Materiały źródłowe

• #1 Melanoma Treatment – NCI

  https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq

  Melanoma is a disease in which malignant (cancer) cells form in melanocytes (cells that color the skin). […] There are different types of treatment for people with melanoma. […] The following types of treatment are used: Surgery, Chemotherapy, Radiation therapy, Immunotherapy, Targeted therapy. […] Treatment of stage 0 is usually surgery to remove the area of abnormal cells and a small amount of normal tissue around it. […] Treatment of stage I melanoma is usually surgery to remove the tumor and some of the normal tissue around it, with or without lymph node mapping and sentinel lymph node biopsy. […] Treatment of stage II melanoma may include: surgery to remove the tumor and some of the normal tissue around it, with lymph node mapping and sentinel lymph node biopsy. If cancer is found in the sentinel lymph node, more lymph nodes may be removed.

• #2 Melanoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/melanoma/diagnosis-treatment/drc-20374888

  Melanoma treatment often starts with surgery to remove the cancer. Other treatments may include radiation therapy and treatment with medicine. Treatment for melanoma depends on several factors. These factors include the stage of your cancer, your overall health and your own preferences. […] Treatment for melanoma usually includes surgery to remove the melanoma. A very thin melanoma may be removed entirely during the biopsy and require no further treatment. Otherwise, your surgeon will remove the cancer as well as some of the healthy tissue around it. […] For people with melanomas that are small and thin, surgery might be the only treatment needed. If the melanoma has grown deeper into the skin, there might be a risk that the cancer has spread. So other treatments are often used to make sure all the cancer cells are killed.

• #3 Immunotherapy and cell therapy expand treatment possibilities for melanoma patients | Stanford Cancer Institute

  https://med.stanford.edu/cancer/about/news/melanoma.html

  Immunotherapy and cell therapy expand treatment possibilities for melanoma patients […] Melanoma is the deadliest form of skin cancer, despite only accounting for 1% of all skin cancers. […] To learn more about current melanoma treatment and advances in treatment, we talked with SCI member Allison Betof Warner, MD, PhD, leader of Stanfords Melanoma Cutaneous Oncology Clinical Research Group. […] Stage 4 melanoma survival rate has drastically improved with immunotherapy […] In the past, the survival outcomes after a stage 4 melanoma diagnosis used to be measured in months, but now more than half of patients live for five years or more after being diagnosed. This is because the standard of care has shifted to immunotherapy, which is exceptionally effective for melanoma in part due to the high tumor mutation burden caused by UV damage.

• #4 Melanoma Treatment – Melanoma Institute Australia

  https://melanoma.org.au/for-patients/melanoma-treatment/

  Your doctor will recommend the best treatment option based on the stage of your melanoma, together with other factors such as your age and general health. […] The most common treatment for Stage 0, I or II (early stage) melanoma is surgery. If caught early, 90% of melanomas can be cured with simple surgery alone. […] If you have been diagnosed with Stage III or IV (advanced) melanoma you may be recommended to have a combination of different treatments including surgery, drug therapy, and radiation. […] Surgery is the most common treatment for melanoma, however its purpose varies depending on how far the cancer has progressed. […] For early stage melanoma, a biopsy may be all that’s required i.e. removal of the tumour by excising it. A wide local excision may also be required, where the skin surrounding the melanoma is removed to reduce the risk of the melanoma recurring.

• #5 Melanoma Treatment (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65950/

  This PDQ cancer information summary has current information about the treatment of melanoma. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. […] Different types of treatment are available for people with melanoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for people with cancer. […] The following types of treatment are used: Surgery, Chemotherapy, Radiation therapy, Immunotherapy, Targeted therapy. […] Surgery to remove the tumor is the primary treatment for all stages of melanoma. A wide local excision is used to remove the melanoma and some of the normal tissue around it.

• #6 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  The type of treatment(s) your doctor recommends will depend mainly on the stage and location of the melanoma. […] Stage 0 melanoma (melanoma in situ) has not grown deeper than the top layer of the skin (the epidermis). It is usually treated by surgery (wide excision) to remove the melanoma and a small margin of normal skin around it. […] Some doctors may consider the use of imiquimod cream (Zyclara) or radiation therapy after surgery if not all the cancer cells can be removed for some reason, although not all doctors agree with this. […] Stage I melanomas have grown into deeper layers of the skin, but they haven’t grown beyond the area where they started. […] These cancers are typically treated by wide excision (surgery to remove the tumor as well as a margin of normal skin around it).

• #7 Melanoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/melanoma/diagnosis-treatment/drc-20374888

  Melanoma treatment often starts with surgery to remove the cancer. Other treatments may include radiation therapy and treatment with medicine. Treatment for melanoma depends on several factors. These factors include the stage of your cancer, your overall health and your own preferences. […] Treatment for melanoma usually includes surgery to remove the melanoma. A very thin melanoma may be removed entirely during the biopsy and require no further treatment. Otherwise, your surgeon will remove the cancer as well as some of the healthy tissue around it. […] For people with melanomas that are small and thin, surgery might be the only treatment needed. If the melanoma has grown deeper into the skin, there might be a risk that the cancer has spread. So other treatments are often used to make sure all the cancer cells are killed.

• #8 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Some doctors may recommend a sentinel lymph node biopsy (SLNB) to look for cancer in nearby lymph nodes, especially if the melanoma is stage IB or has other traits that make it more likely to have spread. […] If the SLNB does not find cancer cells in the lymph nodes, then no further treatment is needed, although close follow-up is still important. […] If cancer cells are found on the SLNB (which changes the cancer stage to stage III), a lymph node dissection (removal of all lymph nodes near the cancer) might be recommended. […] For certain stage II melanomas, the immune checkpoint inhibitor pembrolizumab (Keytruda) might be given after surgery to help reduce the risk of the cancer returning. […] Surgical treatment for stage III melanoma usually requires wide excision of the primary tumor as in earlier stages, along with a lymph node dissection (where all the nearby lymph nodes are surgically removed).

• #9 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  Patients who are younger, female, and who have melanomas on their extremities generally have better prognoses. […] Long-term follow-up is important for detection of recurrence, managing long-term effects, and surveillance of new lesions. […] Surgical excision remains the primary modality for treating localized melanoma. […] Localized melanoma is excised with margins proportional to the microstage of the primary lesion. […] Lymphatic mapping and SLNB should be considered to assess the presence of occult metastasis in the regional lymph nodes of patients with primary tumors measuring at least 0.8 mm thick with clinically negative nodes. […] Adjuvant therapy options for patients at high risk of recurrence after complete resection include checkpoint inhibitors and combination signal transduction inhibitor therapy.

• #10 Melanoma Treatment – Melanoma Institute Australia

  https://melanoma.org.au/for-patients/melanoma-treatment/

  For later stage melanoma, surgery is used as a diagnostic tool to assess how far the cancer has spread. Patients may require surgery to remove lymph nodes. […] A lymph node dissection may be performed in select cases. This may happen at the same time as the wide local excision or as a subsequent surgery. Your surgeon will talk to you about the benefits of undergoing a lymph node dissection. […] Currently, there are two main types of drug therapy used to treat melanoma targeted therapy and immunotherapy: […] Targeted therapies are drugs that block the growth of cancer by interfering with specific gene mutations in melanoma cells that allow melanoma to grow and spread. […] Immunotherapy can be effective in shrinking melanoma metastases in advanced melanoma patients and reducing the risk of melanoma recurrence, regardless of your genetic mutation test result. […] Radiation therapy uses x-rays to target and kill cancer cells by damaging their DNA. Normal cells can repair damage to their DNA, but cancer cells are less able to do this and therefore die when affected by radiation therapy.

• #11 Melanoma Treatments | Melanoma | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/melanoma/melanoma-treatments/

  Regional lymph-node dissection: If the cancer has spread to the lymph nodes near the cancerous area, your surgeon might need to remove a large number of nodes and examine them for the presence of melanoma. […] Reconstructive surgery: UT Southwestern surgeons can sometimes use reconstructive surgery to prevent or treat scarring or disfigurement after skin cancer treatment, especially when a tumor is large. […] Radiation therapy uses external radiation delivered by beams of high-energy X-rays to target and destroy melanoma cells or prevent them from growing. […] UT Southwestern offers both traditional radiation therapy and stereotactic radiosurgery to treat melanoma that has spread to the brain or other organs that cant be treated with surgery or when a patient isnt healthy enough for surgery.

• #12 Melanoma Treatment – Melanoma Institute Australia

  https://melanoma.org.au/for-patients/melanoma-treatment/

  Your doctor will recommend the best treatment option based on the stage of your melanoma, together with other factors such as your age and general health. […] The most common treatment for Stage 0, I or II (early stage) melanoma is surgery. If caught early, 90% of melanomas can be cured with simple surgery alone. […] If you have been diagnosed with Stage III or IV (advanced) melanoma you may be recommended to have a combination of different treatments including surgery, drug therapy, and radiation. […] Surgery is the most common treatment for melanoma, however its purpose varies depending on how far the cancer has progressed. […] For early stage melanoma, a biopsy may be all that’s required i.e. removal of the tumour by excising it. A wide local excision may also be required, where the skin surrounding the melanoma is removed to reduce the risk of the melanoma recurring.

• #13 Treatment for Early Melanoma | Cancer Council NSW

  https://www.cancercouncil.com.au/melanoma/treatment/

  Learn about the best treatment for early melanoma, including the importance of surgery and potential neoadjuvant options. […] Surgery is the most common treatment for melanoma that is found early (stages 0–2 or localised melanoma). If found early, 90% of melanomas can be cured with surgery alone. […] If the risk of the melanoma spreading is high or it has spread to nearby lymph nodes or tissues (stage 3 or regional melanoma), treatment may also include removing lymph nodes and additional (adjuvant) treatments. […] Your doctor may suggest you have drug treatment before surgery (neoadjuvant treatment).

• #14 Immunotherapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/immunotherapy-melanoma

  Dr. Michael Postow is a leader in checkpoint inhibitor therapy, a type of immunotherapy. […] Immunotherapy is a method of treating cancer that uses drugs to empower the immune system to recognize and fight cancer. MSK has been a pioneer in developing immunotherapy. The approach has proven very effective in treating advanced melanoma. […] The immunotherapy drugs most commonly used to treat melanoma are called checkpoint inhibitors. Checkpoint inhibitors work by unleashing T cells (immune cells that seek out and destroy tumors). This therapy is sometimes called immune checkpoint blockade because the molecule that acts as a natural brake on T cells the checkpoint is blocked by the drug, thereby releasing the brake. […] Three checkpoint inhibitor drugs are currently available to treat advanced melanoma. These are ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda).

• #15 Melanoma Treatment

  https://www.skincancer.org/skin-cancer-information/melanoma/melanoma-treatments/

  Advanced melanomas are those that have spread beyond the original tumor, most often reaching the lymph nodes and/or distant organs and becoming more difficult to treat. […] In recent years, new immunotherapies and targeted therapies have achieved positive results in many patients with stage III and stage IV melanoma. […] Patients with stage III melanoma now have options for supplemental or “adjuvant” treatment – medicines that enhance the effectiveness of surgery, with the goal of preventing or delaying relapse and extending survival, ideally achieving a cure. […] Pioneering breakthroughs in immunotherapy — the use of medicines to stimulate a patient’s immune system to destroy cancer cells — have led to significant progress in treating patients with advanced melanoma. […] Immunotherapies boost the body’s ability to fight melanoma and other cancers by using synthetic versions of natural immune system proteins, or by enabling the release of cells that attack tumors.

• #16 Immunotherapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/immunotherapy-melanoma

  Ipilimumab (Yervoy) can be effective for people with metastatic melanoma and stage III melanoma that cannot be removed completely with surgery. Ipilimumab works by blocking an immune molecule called CTLA-4. […] Nivolumab (Opdivo) and pembrolizumab (Keytruda) belong to a class of drugs called PD-1 blockers. Both of these medications work by inhibiting the molecule PD-1. These drugs have proven very effective against metastatic melanoma and stage III melanoma that cannot be removed completely with surgery. […] Another approach to advanced melanoma treatment involves combining ipilimumab and nivolumab. The idea is that the two classes of drugs are more effective together than when used alone. […] Side effects are an important consideration when making decisions about immunotherapy treatment for melanoma.

• #17 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Immunotherapy — Several different types of immunotherapy have been developed, the most important of which are checkpoint inhibitors (nivolumab [brand name: Opdivo], pembrolizumab [brand name: Keytruda], ipilimumab [brand name: Yervoy], and nivolumab-relatlimab [brand name: Opdualag]), which have replaced high-dose interleukin-2 (IL-2) […] Nivolumab and pembrolizumab — The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) unleash the body’s immune system to reject the melanoma. […] Treatment with nivolumab, pembrolizumab, or the combination of nivolumab plus ipilimumab may decrease the extent of your melanoma and help you live longer. […] Targeted therapy — About one-half of metastatic melanomas contain a specific mutation at a particular spot in one gene (BRAF) that causes the cell to make a particular protein that drives the growth of cancer cells.

• #18 Immunotherapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/immunotherapy-melanoma

  Ipilimumab (Yervoy) can be effective for people with metastatic melanoma and stage III melanoma that cannot be removed completely with surgery. Ipilimumab works by blocking an immune molecule called CTLA-4. […] Nivolumab (Opdivo) and pembrolizumab (Keytruda) belong to a class of drugs called PD-1 blockers. Both of these medications work by inhibiting the molecule PD-1. These drugs have proven very effective against metastatic melanoma and stage III melanoma that cannot be removed completely with surgery. […] Another approach to advanced melanoma treatment involves combining ipilimumab and nivolumab. The idea is that the two classes of drugs are more effective together than when used alone. […] Side effects are an important consideration when making decisions about immunotherapy treatment for melanoma.

• #19 Malignant Melanoma Medication: Antineoplastic Agents, Biological Response Modulators, Oncolytic Immunotherapy, ImmTACs, Tumor Infiltrating Lymphocytes (TILs)

  https://emedicine.medscape.com/article/280245-medication

  The first autologous tumor-infiltrating lymphocytes (TILs) preparation, lifileucel, was approved by the FDA for unresectable or metastatic melanoma. […] Ipilimumab is able to inhibit the effects of CTLA-4 on T cells and allows the expansion of naturally developed melanoma-specific cytotoxic T-cells. This agent is the first new agent to be approved for melanoma in over a decade. […] It is indicated for the treatment of unresectable or metastatic melanoma in adults and adolescents aged 12 y or older. […] Pembrolizumab is a programed cell death-1 protein (PD-1) inhibitor. It is indicated as first-line treatment for unresectable or metastatic melanoma. […] Nivolumab is a monoclonal antibody to programmed cell death-1 protein (PD-1). It is indicated as a single agent for unresectable or metastatic melanoma and disease progression following ipilimumab treatment and, if BRAF V600 mutation positive, a BRAF inhibitor. […] Lifileucel is indicated for unresectable or metastatic melanoma in adults previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is the first autologous T-cell therapy approved for a solid tumor cancer.

• #20 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Treatment with dacarbazine, a chemotherapeutic agent that was introduced in the 1970s, was the standard of care for melanoma patients until targeted therapy was introduced in 2011. Dacarbazine alkylates DNA non-specifically to block DNA replication. The rate of objective tumor responses in patients on dacarbazine ranged from 13 to 20%, with nearly all responses being partial. In addition, dacarbazine caused severe adverse effects (AE) in patients. […] BRAF is the most commonly mutated gene in melanoma, and it is therefore an attractive candidate for targeted therapy. One of the first inhibitors developed against mutated BRAF was sorafenib, which is a multikinase inhibitor that targets CRAF, both wild-type and mutant BRAF, and multiple receptor tyrosine kinases (RTKs). However, the efficacy of sorafenib was limited both as a single agent and in combination with chemotherapeutics, likely due to its weak affinity for BRAF. As a result, inhibitors that could bind specifically to mutated BRAF were developed, such as vemurafenib, dabrafenib and encorafenib. These inhibitors bind to the ATP-binding pocket of BRAF with increased affinity for BRAF V600E mutation which enhances their selectivity. They demonstrated increased efficacy over chemotherapeutic agents with a better dose-dependent tumor inhibition in preclinical studies, a higher rate of objective responses (OR) and improved overall survival (OS) in clinical trials. Despite the improved efficacy of BRAF inhibitors (BRAFi) over chemotherapy, in most cases disease progression occurs after 6–7 months of treatment due to acquired resistance. The molecular mechanism underlying this induced resistance is often the reactivation of MAPK signaling through initiation of the MEK cascade; this will be discussed in detail later in the review.

• #21 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  These drugs prolong the time until there is disease growth and extend overall survival in people with BRAF-mutant melanoma. […] Chemotherapy — Chemotherapy uses medicines such as dacarbazine or temozolomide with or without cisplatin to stop or slow the growth of cancer cells by interfering with the ability of cancer cells to divide or reproduce. […] Surgery — Surgery may be recommended if melanoma has spread to only one or a very limited number of sites. […] Radiation therapy — Melanoma frequently spreads to the brain. Treatment options may include surgery, immunotherapy, or radiation. […] END-OF-LIFE CARE […] Significant progress has been made in the treatment of metastatic melanoma. […] The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) and the combinations of nivolumab plus ipilimumab or nivolumab plus relatlimab are effective for controlling metastatic melanoma and prolonging life.

• #22 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  The FDA approved IL-2 in 1998 because of durable complete response rates in a minority of patients (6%-7%) with previously treated metastatic melanoma in eight phase I and II studies. […] The combination of antiPD-1 and antiCTLA-4 immunotherapies (nivolumab and ipilimumab) also prolongs PFS and OS compared with ipilimumab, but the combination is associated with significant toxicity. […] The efficacy seen with immunotherapy is independent of BRAF variant status. […] Combinations of BRAF and MEK inhibitors have consistently shown superior efficacy compared with BRAF monotherapy.

• #23 Treatment of Metastatic Melanoma: An Overview

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2737459/

  High-dose interleukin-2 (HD IL-2 [Proleukin]), approved by the FDA in 1998 for metastatic melanoma, benefits a small subset of patients. […] Systemic therapy is the mainstay of therapy for most patients with stage IV melanoma. […] Cytotoxic chemotherapy has been used for the treatment of metastatic melanoma for over 3 decades. […] Dacarbazine is typically administered intravenously at a dose of 150 to 200 mg/m2/d for 5 days or at a single dose of 800 to 1,000 mg/m2, with doses repeated every 3 to 4 weeks. […] Despite its modest efficacy and lack of data for survival benefit, dacarbazine continues to be the standard treatment of metastatic melanoma. […] The modest antitumor activity of the chemotherapeutic agents mentioned above led to investigation of combinations of these agents to improve outcomes.

• #24 FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma

  Today, the U.S. Food and Drug Administration approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor). […] Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal, said Peter Marks, M.D., Ph.D., director of the FDAs Center for Biologics Evaluation and Research (CBER). The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options.

• #25 Cell Therapy is Now on The Table for Metastatic Melanoma – InventUMPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–button

  https://news.med.miami.edu/cell-therapy-on-the-table-for-metastatic-melanoma/

  Cell Therapy is Now on The Table for Metastatic Melanoma […] The first cellular therapy for metastatic melanoma was recently approved by the FDA. This is the first cellular therapy approved for any solid tumor and is meant to treat advanced cases of the skin cancer where previous treatments have failed. […] The therapy, known as tumor-infiltrating lymphocyte therapy (TIL), uses a patient’s own immune cells to battle their cancer and will soon be available to patients at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. […] Trials testing the newly approved TIL therapy, lifileucel, showed a response rate of 32% among 153 participants. The therapy is approved for patients whose melanoma has advanced despite treatment with other forms of immunotherapy, namely checkpoint inhibitors and targeted therapy, which is used for melanomas that carry a common mutation in the BRAF gene.

• #26 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  After surgery, (additional) adjuvant treatment with immune checkpoint inhibitors or with targeted therapy drugs (for cancers with BRAF gene changes) may help lower the risk of the melanoma coming back. […] Stage IV melanomas have already spread (metastasized) to other parts of the body, such as distant lymph nodes, areas of skin, or other organs. […] The treatment of widespread melanomas has changed in recent years as newer forms of immunotherapy and targeted drugs have been shown to be more effective than chemotherapy. […] Immunotherapy drugs called checkpoint inhibitors are often the first treatment. […] In about half of all melanomas, the cancer cells have BRAF gene changes. These melanomas often respond to treatment with targeted therapy drugs typically a combination of a BRAF inhibitor and a MEK inhibitor.

• #27 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  The reason for offering adjuvant treatment is to try to kill these cancer cells and increase the chance of cure after surgery. […] Adjuvant therapy usually lasts for 1 year but could be less if you have had neoadjuvant treatment before your surgery. […] Adjuvant therapy can reduce the risk of your melanoma coming back (recurrence) after surgery. […] As with all drug treatments, some people will experience side effects with adjuvant therapy, but these do not affect everyone. […] Some patients who have had surgery for Stage 2B or 2C melanoma may be offered adjuvant immunotherapy to reduce their chance of further problems from the melanoma. […] Pembrolizumab is currently the only treatment approved for stage 2B or 2C melanoma, however, there are ongoing clinical trials looking at other treatments.

• #28 Immunotherapy for Melanoma – Cancer Research Institute

  https://www.cancerresearch.org/cancer-types/melanoma

  Despite the recent advancements in FDA-approved melanoma therapies, many advanced metastatic melanoma patients still face a significant mortality risk. […] Research into immunotherapy for melanoma continues to evolve, with CRI playing a crucial role in funding innovative studies. […] A recent study published by the National Institutes of Health (NIH) shows that immunotherapy improves survival rates for many melanoma patients. […] The effectiveness of immunotherapy can vary, influenced by factors such as the tumor’s characteristics and the patient’s immune response. […] The frequency of immunotherapy administration can vary widely depending on the specific regimen. […] Commonly used and effective treatments include checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy), sometimes used in combination for enhanced effectiveness.

• #29 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Treatment with dacarbazine, a chemotherapeutic agent that was introduced in the 1970s, was the standard of care for melanoma patients until targeted therapy was introduced in 2011. Dacarbazine alkylates DNA non-specifically to block DNA replication. The rate of objective tumor responses in patients on dacarbazine ranged from 13 to 20%, with nearly all responses being partial. In addition, dacarbazine caused severe adverse effects (AE) in patients. […] BRAF is the most commonly mutated gene in melanoma, and it is therefore an attractive candidate for targeted therapy. One of the first inhibitors developed against mutated BRAF was sorafenib, which is a multikinase inhibitor that targets CRAF, both wild-type and mutant BRAF, and multiple receptor tyrosine kinases (RTKs). However, the efficacy of sorafenib was limited both as a single agent and in combination with chemotherapeutics, likely due to its weak affinity for BRAF. As a result, inhibitors that could bind specifically to mutated BRAF were developed, such as vemurafenib, dabrafenib and encorafenib. These inhibitors bind to the ATP-binding pocket of BRAF with increased affinity for BRAF V600E mutation which enhances their selectivity. They demonstrated increased efficacy over chemotherapeutic agents with a better dose-dependent tumor inhibition in preclinical studies, a higher rate of objective responses (OR) and improved overall survival (OS) in clinical trials. Despite the improved efficacy of BRAF inhibitors (BRAFi) over chemotherapy, in most cases disease progression occurs after 6–7 months of treatment due to acquired resistance. The molecular mechanism underlying this induced resistance is often the reactivation of MAPK signaling through initiation of the MEK cascade; this will be discussed in detail later in the review.

• #30 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Immunotherapy — Several different types of immunotherapy have been developed, the most important of which are checkpoint inhibitors (nivolumab [brand name: Opdivo], pembrolizumab [brand name: Keytruda], ipilimumab [brand name: Yervoy], and nivolumab-relatlimab [brand name: Opdualag]), which have replaced high-dose interleukin-2 (IL-2) […] Nivolumab and pembrolizumab — The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) unleash the body’s immune system to reject the melanoma. […] Treatment with nivolumab, pembrolizumab, or the combination of nivolumab plus ipilimumab may decrease the extent of your melanoma and help you live longer. […] Targeted therapy — About one-half of metastatic melanomas contain a specific mutation at a particular spot in one gene (BRAF) that causes the cell to make a particular protein that drives the growth of cancer cells.

• #31 Targeted therapy for melanoma | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/targeted-therapy-for-melanoma

  Targeted therapy drugs target something in or around the cancer cell that is helping it grow and survive. […] You only have targeted therapy to treat melanoma if tests show that the cancer cells have a change (mutation) in a gene called BRAF. This treatment has not been shown to be useful or safe unless the cancer cells have this change. […] You usually have 2 targeted therapy drugs in combination to treat melanoma. […] These drugs are also called cancer growth inhibitors. Each combination includes a drug called a braf inhibitor. The drugs block the signals that tell cells in the body to develop and divide. By blocking the signals, these drugs may stop cancer cells from developing or dividing. […] Sometimes, dabrafenib and trametinib are used after surgery to reduce the risk of melanoma coming back. This is called adjuvant treatment. These drugs are used to treat melanoma if it cannot be removed with surgery or has spread (advanced melanoma).

• #32 FDA Approved Drugs – AIM at Melanoma Foundation

  https://www.aimatmelanoma.org/fda-approved-drugs/

  In a Phase II study, C-144-01 trial in which 31.4 percent of 153 patients responded to Amtagvi, and more than half of these patients were still responding after a year. Keytruda is a humanized monoclonal antibody designed to block a cellular target known as PD-1, which results in an anti-tumor immune response. Opdivo works by increasing the ability of the body’s immune system to fight advanced melanoma. Yervoy is an anti-CTLA-4 monoclonal antibody designed to restore and strengthen the immune system by supporting the activation and proliferation of T-cells. […] Mekinist blocks a cellular pathway to stop the growth of melanoma tumors. Tafinlar blocks a cellular pathway to stop the growth of melanoma tumors. Zelboraf blocks a cellular pathway to stop the growth of melanoma tumors. Braftovi in combination with Mektovi blocks a cellular pathway to inhibit the growth of melanoma tumors. Cotellic in combination with Zelboraf blocks a cellular pathway to inhibit the growth of melanoma tumors. […] DTIC is given to shrink or slow the growth of melanoma tumors that have spread throughout the body. DTIC is the only FDA approved chemotherapy drug for the treatment of metastatic melanoma.

• #33 FDA Approved Drugs – AIM at Melanoma Foundation

  https://www.aimatmelanoma.org/fda-approved-drugs/

  In a Phase II study, C-144-01 trial in which 31.4 percent of 153 patients responded to Amtagvi, and more than half of these patients were still responding after a year. Keytruda is a humanized monoclonal antibody designed to block a cellular target known as PD-1, which results in an anti-tumor immune response. Opdivo works by increasing the ability of the body’s immune system to fight advanced melanoma. Yervoy is an anti-CTLA-4 monoclonal antibody designed to restore and strengthen the immune system by supporting the activation and proliferation of T-cells. […] Mekinist blocks a cellular pathway to stop the growth of melanoma tumors. Tafinlar blocks a cellular pathway to stop the growth of melanoma tumors. Zelboraf blocks a cellular pathway to stop the growth of melanoma tumors. Braftovi in combination with Mektovi blocks a cellular pathway to inhibit the growth of melanoma tumors. Cotellic in combination with Zelboraf blocks a cellular pathway to inhibit the growth of melanoma tumors. […] DTIC is given to shrink or slow the growth of melanoma tumors that have spread throughout the body. DTIC is the only FDA approved chemotherapy drug for the treatment of metastatic melanoma.

• #34 Targeted therapy for melanoma | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/targeted-therapy-for-melanoma

  Targeted therapy drugs target something in or around the cancer cell that is helping it grow and survive. […] You only have targeted therapy to treat melanoma if tests show that the cancer cells have a change (mutation) in a gene called BRAF. This treatment has not been shown to be useful or safe unless the cancer cells have this change. […] You usually have 2 targeted therapy drugs in combination to treat melanoma. […] These drugs are also called cancer growth inhibitors. Each combination includes a drug called a braf inhibitor. The drugs block the signals that tell cells in the body to develop and divide. By blocking the signals, these drugs may stop cancer cells from developing or dividing. […] Sometimes, dabrafenib and trametinib are used after surgery to reduce the risk of melanoma coming back. This is called adjuvant treatment. These drugs are used to treat melanoma if it cannot be removed with surgery or has spread (advanced melanoma).

• #35 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  Large randomized trials with nivolumab and pembrolizumab and with combination signal transduction inhibitors (dabrafenib plus trametinib) have shown a clinically significant impact on relapse-free survival (RFS). […] Treatment options for patients with metastatic melanoma have rapidly expanded over the last decade. […] Pembrolizumab, nivolumab, ipilimumab, and relatlimab (in a fixed-dose formulation with nivolumab) are checkpoint inhibitors approved by the FDA. […] Studies indicate that both BRAF and MEK inhibitors can significantly impact the natural history of melanoma, although they do not appear to be curative as single agents. […] The combination of an antiprogrammed death-1 (PD-1) antibody and an anticytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody (nivolumab and ipilimumab) has prolonged progression-free survival (PFS) and overall survival (OS) compared with ipilimumab monotherapy.

• #36 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  If you have been diagnosed with stage 3A, 3B, 3C or 3D melanoma you may be offered adjuvant immunotherapy treatment (pembrolizumab or nivolumab), or BRAF-targeted therapy (dabrafenib and trametinib) if you have a faulty BRAF gene. […] If you have completely resected stage 4 melanoma you may be offered adjuvant immunotherapy treatment. […] Targeted treatments for stage 3 melanoma can be offered if your melanoma contains a BRAF mutation. […] BRAF-targeted treatment is taken twice a day by mouth at home for up to 1 year. […] Immunotherapy uses our immune system to fight cancer. […] It works by helping the immune system recognise and attack cancer cells. […] Immunotherapy treatment is given for up to 1 year and is suitable for patients with BRAF-positive or BRAF-negative melanoma.

• #37 Adjuvant therapies for melanoma

  https://dermnetnz.org/topics/adjuvant-therapies-for-melanoma

  Initial research data on immunotherapy using ipilimumab in stage III metastatic melanoma is from two major studies. The chance of overall survival at 5 years was improved by 28%, and the risk of metastatic melanoma recurrence at 5 years was improved by 24% in those randomised to ipilimumab compared to placebo. […] In the CheckMate 238 trial, the recurrence-free survival was reduced by 35% in those randomised to receive nivolumab compared to ipilimumab with reduced serious adverse events. In the KEYNOTE-054 study, patients randomised to pembrolizumab had a 43% reduction in risk of recurrence or death compared to placebo. […] Studies into BRAF inhibitors and BRAF/MEK dual inhibition for patients with stage III metastatic melanoma were conducted prior to the immunotherapy studies. Key results are listed below. A consistent improvement in the overall survival (OS) of patients was demonstrated with the use of single agent MEK/BRAF inhibition compared to placebo. This benefit was increased with dual inhibition.

• #38 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Treatment with dacarbazine, a chemotherapeutic agent that was introduced in the 1970s, was the standard of care for melanoma patients until targeted therapy was introduced in 2011. Dacarbazine alkylates DNA non-specifically to block DNA replication. The rate of objective tumor responses in patients on dacarbazine ranged from 13 to 20%, with nearly all responses being partial. In addition, dacarbazine caused severe adverse effects (AE) in patients. […] BRAF is the most commonly mutated gene in melanoma, and it is therefore an attractive candidate for targeted therapy. One of the first inhibitors developed against mutated BRAF was sorafenib, which is a multikinase inhibitor that targets CRAF, both wild-type and mutant BRAF, and multiple receptor tyrosine kinases (RTKs). However, the efficacy of sorafenib was limited both as a single agent and in combination with chemotherapeutics, likely due to its weak affinity for BRAF. As a result, inhibitors that could bind specifically to mutated BRAF were developed, such as vemurafenib, dabrafenib and encorafenib. These inhibitors bind to the ATP-binding pocket of BRAF with increased affinity for BRAF V600E mutation which enhances their selectivity. They demonstrated increased efficacy over chemotherapeutic agents with a better dose-dependent tumor inhibition in preclinical studies, a higher rate of objective responses (OR) and improved overall survival (OS) in clinical trials. Despite the improved efficacy of BRAF inhibitors (BRAFi) over chemotherapy, in most cases disease progression occurs after 6–7 months of treatment due to acquired resistance. The molecular mechanism underlying this induced resistance is often the reactivation of MAPK signaling through initiation of the MEK cascade; this will be discussed in detail later in the review.

• #39 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  For patients with stage III in-transit disease, primary treatment options include the following: Complete resection (preferred, if feasible) […] SLNB for resectable disease […] Hyperthermic perfusion/infusion with melphalan for localized multiple lesions in a single extremity or recurrent lesions in a single limb […] Talimogene laherparepvec is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrence after initial surgery […] Optimal regimens and durations for neoadjuvant systemic therapy are not well established, but the following are typically used: Pembrolizumab 200 mg IV q3wk three doses or Ipilimumab 1 mg/kg IV plus nivolumab 3 mg/kg q3wk for two cycles […] Combination treatment provides better response and control of the disease and is often used in patients with advanced or metastatic disease who clinically are able to tolerate this approach

• #40 Radiation Therapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/radiation-therapy-melanoma

  Christopher Barker is one of the countrys leading experts on the use of radiation therapy to treat melanoma. […] Radiation therapy is a treatment for melanoma that involves directing a beam of high-energy particles at a tumor. When the beam reaches the tumor, it destroys the cancer cells by damaging their DNA. […] Radiation therapy can be used in one of several ways to treat melanoma. It may be recommended after melanoma surgery to prevent the cancer from coming back. Some people may receive radiation in combination with immunotherapy or other drug therapies to achieve a more lasting response to treatment. Radiation can also help ease symptoms caused by tumors. […] Sometimes we recommend radiation therapy in the area where surgery was performed to remove melanoma. For some people, this approach may reduce the chance that the melanoma will come back in that specific area.

• #41 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Significant progress has been made in the last few decades in melanoma therapeutics, most notably in targeted therapy and immunotherapy. These approaches have greatly improved treatment response outcomes; however, they remain limited in their abilities to hinder disease progression due, in part, to the onset of acquired resistance. In parallel, intrinsic resistance to therapy remains an issue to be resolved. In this review, we summarize currently available therapeutic options for melanoma treatment and focus on possible mechanisms that drive therapeutic resistance. A better understanding of therapy resistance will provide improved rational strategies to overcome these obstacles. […] Surgical tumor removal has been the standard of care for patients with primary melanoma. Radiation therapy, which is common for many other cancer types, has not gained widespread use in melanoma, as skin tumors are usually radioresistant. Instead, therapeutic agent administration is a more likely treatment option for most patients. However, radiotherapy remains an option for patients with inoperable tumors, as well as imiquimod cream, a local immunomodulator prescribed to some patients with early-stage melanoma.

• #42 Adjuvant therapies for melanoma

  https://dermnetnz.org/topics/adjuvant-therapies-for-melanoma

  Local control of melanoma may be enhanced by adjuvant radiotherapy if the risk of local recurrence remains unacceptably high after surgical excision such as with: Inadequate wide excision margins, often due to anatomical or cosmetic constraints around the eye/conjunctiva, nose, lips, or ears, Satellite lesions, Neurotropism (perineural invasion) on histology, Desmoplastic melanoma, due to its tendency for local recurrence. […] Although randomised controlled trials have not evaluated the benefit of adjuvant radiotherapy, several large observational cohorts have reported positive results with 50-85% improvement in risk of local recurrence. Possible evidence was also observed for decreased nodal recurrence. […] The local inflammatory effects resulting from radiation therapy may provide a synergistic boost to the efficacy of immunotherapy. Further research is underway to evaluate its benefits.

• #43 Radiation Therapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/radiation-therapy-melanoma

  Christopher Barker is one of the countrys leading experts on the use of radiation therapy to treat melanoma. […] Radiation therapy is a treatment for melanoma that involves directing a beam of high-energy particles at a tumor. When the beam reaches the tumor, it destroys the cancer cells by damaging their DNA. […] Radiation therapy can be used in one of several ways to treat melanoma. It may be recommended after melanoma surgery to prevent the cancer from coming back. Some people may receive radiation in combination with immunotherapy or other drug therapies to achieve a more lasting response to treatment. Radiation can also help ease symptoms caused by tumors. […] Sometimes we recommend radiation therapy in the area where surgery was performed to remove melanoma. For some people, this approach may reduce the chance that the melanoma will come back in that specific area.

• #44 Radiation Therapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/radiation-therapy-melanoma

  Radiation can also help people with melanoma that has spread (metastasized) to other areas of the body. For example, when melanoma spreads to the brain, one option may be stereotactic radiosurgery. This procedure allows doctors to deliver a single high dose of radiation directly to a tumor. It can eliminate the tumor with few side effects. […] IMRT can be combined with image-guidance technology. This approach is called IG-IMRT. It allows for a precise delivery thats more effective than other forms of radiation therapy at controlling melanoma. Some metastatic tumors can be eliminated when high doses of radiation are used with stereotactic techniques, also known as SBRT.

• #45 Treatments for metastatic melanoma skin cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/melanoma-skin/treatment/metastatic

  Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them to stop the growth and spread of cancer. Targeted therapy is usually offered for unresectable locoregional or metastatic melanoma with certain gene changes (mutations), including mutations in the BRAF gene. […] Surgery is rarely used to treat metastatic melanoma. You may be offered surgery if cancer is only in: 1 or a few small areas on or just under the skin, 1 group of lymph nodes, a lung, the liver, the brain or the small intestine. […] Radiation therapy uses high-energy rays or particles to destroy cancer cells. You may be offered radiation therapy for metastatic melanoma. It is also used as a palliative treatment to control symptoms from metastases. […] Chemotherapy uses drugs to destroy cancer cells. It may be offered to control symptoms of metastatic melanoma (called palliative chemotherapy). It may also be used to treat metastatic melanoma if other treatments haven’t worked.

• #46 Melanoma Treatment Options | Targeting Center AU & NZ

  https://www.targetingcancer.com.au/treatment-by-cancer-type/melanoma/

  When radiation therapy is recommended, it’s usually after surgery. This is called adjuvant therapy. It’s also used to ease symptoms in people with advanced melanoma. […] Sometimes, radiation therapy is used as the main treatment for early melanomas that can’t be treated with surgery. […] External Beam Radiation Therapy (EBRT) is the most common type of radiation therapy used for melanoma. […] Radiation oncologists often use Volumetric Arc Therapy (VMAT) or stereotactic radiotherapy, which are advanced types of External Beam Radiation Therapy (EBRT), to carefully deliver radiation to the areas that need to be treated. […] Superficial Radiation Therapy (SXRT) is another way to treat melanoma. […] Radiation therapy is more effective with fewer side effects than ever before. […] Recent advances mean radiation oncologists can effectively treat the cancer while getting less radiation on healthy body parts. This means much fewer side effects.

• #47 Melanoma Treatment

  https://www.skincancer.org/skin-cancer-information/melanoma/melanoma-treatments/

  Immune checkpoint inhibitors are given intravenously to melanoma patients to stop checkpoint molecules from inhibiting T cells. This enables the immune system to release waves of T cells to attack and kill cancer cells. […] In 2011, vermurafenib became the first targeted therapy approved for advanced melanoma patients. […] These targeted drugs interrupt and deactivate the tumor growth pathway driven by the genetic change in BRAF, delaying the progression of the disease, shrinking tumors and extending the life of patients. […] Since immunotherapies and targeted therapies produce vastly superior results, chemotherapy is no longer a frontline therapy. […] Radiation is rarely used to treat a primary melanoma tumor, but may be used to treat melanomas that have spread to the brain or other distant sites to shrink tumors and decrease pain, improve comfort and mobility. […] If you have been diagnosed with advanced melanoma, you may be eligible to participate in a clinical trial – a carefully controlled research study using new or experimental treatments.

• #48 Radiation Therapy for Melanoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/melanoma/treatment/radiation-therapy-melanoma

  Radiation can also help people with melanoma that has spread (metastasized) to other areas of the body. For example, when melanoma spreads to the brain, one option may be stereotactic radiosurgery. This procedure allows doctors to deliver a single high dose of radiation directly to a tumor. It can eliminate the tumor with few side effects. […] IMRT can be combined with image-guidance technology. This approach is called IG-IMRT. It allows for a precise delivery thats more effective than other forms of radiation therapy at controlling melanoma. Some metastatic tumors can be eliminated when high doses of radiation are used with stereotactic techniques, also known as SBRT.

• #49 Treatment for Melanoma | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/diseases/melanoma/treatment.html

  If your melanoma is localized, meaning it is just on your skin, you may need only a simple excision (removing it by cutting it out). […] Thicker melanomas tend to spread to nearby lymph nodes, which need to be checked for cancer and possibly removed. […] Immunotherapies harness your body’s immune system to fight your cancer. […] Immune checkpoint inhibitors used for melanoma include: Pembrolizumab (Keytruda) and nivolumab (Opdivo). […] Targeted therapies work selectively against cancer cells, rather than affecting all fast-growing cells, like standard chemotherapy does. […] Radiation therapy is often given to people with melanoma: After surgery to decrease the odds of cancer returning. […] Proton therapy is very effective in achieving local control of the melanoma, and does not worsen survival rates for the patient.

• #50 Melanoma Treatment Options | Targeting Center AU & NZ

  https://www.targetingcancer.com.au/treatment-by-cancer-type/melanoma/

  Side effects from radiation therapy vary between people, even for those having the same treatment. […] While some people feel no side effects, some feel mild side effects, such as tiredness or skin redness during and/or just after treatment. These usually get better within a few weeks. […] Serious side effects that start later (months to years after the radiation therapy) are rare. […] Early side effects of radiation therapy may include: Fatigue: This is very common in the second half of treatment and varies between people. […] Skin reddening and irritation: The skin may become red and itchy during treatment. Blisters and peeling can also occur. […] Hair loss: Hair in the treatment area may fall out during or after radiation therapy. This can be temporary or permanent. […] Late side effects vary between people and can happen a few months to a few years after treatment.

• #51 Melanoma Treatment Options | Targeting Center AU & NZ

  https://www.targetingcancer.com.au/treatment-by-cancer-type/melanoma/

  Skin and underneath soft tissue changes: Lasting skin changes are usually cosmetic and can be managed. […] Skin ulceration or ulcer: This is a very rare side effect of radiation treatment to the skin. […] Swelling of an arm, leg or around the face: This is called lymphoedema. […] Second cancer: Cancers caused by radiation therapy are a very rare side effect. […] To prevent skin issues after radiation therapy, it’s important to follow the advice of your treating team. […] If a skin ulcer doesn’t heal after radiation, surgery can help.

• #52 Treatment of Metastatic Melanoma: An Overview

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2737459/

  The 10-year survival rate for patients with metastatic melanoma is less than 10%. […] Although surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy is the mainstay of treatment for most patients. […] Single-agent chemotherapy is well tolerated but is associated with response rates of only 5% to 20%. […] Combination chemotherapy and biochemotherapy may improve objective response rates but do not extend survival and are associated with greater toxicity. […] Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients. […] More than 3 decades after its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be the standard of care for most patients with this disease.

• #53 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) […] Treatment of metastatic melanoma focuses on: […] Drug treatments — There are three main categories of drug treatments: […] Immunotherapy – Drugs that stimulate or unleash your immune system to attack and kill the cancer cells […] Targeted therapy – Drugs that inhibit specific enzymes or molecules important to the cancer cells […] Chemotherapy – Drugs that stop or slow the growth of cancer cells by interfering with their ability to divide or reproduce themselves […] Advances in the use of immunotherapy and targeted therapy have improved survival for many people with melanoma. Most people will get immunotherapy as the first treatment. Targeted therapy, if a person is a candidate, is often used when the melanoma is no longer being controlled by immunotherapy. Although chemotherapy was widely used in the past, it now has a limited role for people whose disease can no longer be controlled with either immunotherapy or targeted therapy.

• #54 Melanoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/melanoma/diagnosis-treatment/drc-20374888

  Chemotherapy might be an option to help control melanoma that doesn’t respond to other treatments. It might be used when immunotherapy or targeted therapy aren’t helping. […] Sometimes chemotherapy can be given in a vein in your arm or leg in a procedure called isolated limb perfusion. During this procedure, blood in your arm or leg isn’t allowed to travel to other areas of your body for a short time. This helps keep the chemotherapy medicines near the melanoma and doesn’t affect other parts of your body.

• #55 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Chemotherapy (chemo) can help some people with stage IV melanoma, but other treatments are usually tried first. […] Because stage IV melanoma is often hard to cure with current treatments, people may want to think about taking part in a clinical trial. […] Treatment of melanoma that comes back after initial treatment depends on where in the body the melanoma is, what treatments a person has already had, the person’s overall health and preferences, and other factors. […] If melanoma recurs in nearby lymph vessels in or just under the skin (known as in-transit recurrence), it should be removed with surgery, if possible. […] Lymph node recurrence is typically treated by lymph node dissection if it can be done, sometimes followed by adjuvant (additional) treatments such as radiation therapy and/or immunotherapy or targeted therapy (for cancers with BRAF gene changes).

• #56 Treatments for metastatic melanoma skin cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/melanoma-skin/treatment/metastatic

  Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them to stop the growth and spread of cancer. Targeted therapy is usually offered for unresectable locoregional or metastatic melanoma with certain gene changes (mutations), including mutations in the BRAF gene. […] Surgery is rarely used to treat metastatic melanoma. You may be offered surgery if cancer is only in: 1 or a few small areas on or just under the skin, 1 group of lymph nodes, a lung, the liver, the brain or the small intestine. […] Radiation therapy uses high-energy rays or particles to destroy cancer cells. You may be offered radiation therapy for metastatic melanoma. It is also used as a palliative treatment to control symptoms from metastases. […] Chemotherapy uses drugs to destroy cancer cells. It may be offered to control symptoms of metastatic melanoma (called palliative chemotherapy). It may also be used to treat metastatic melanoma if other treatments haven’t worked.

• #57 Cancer Society NZ — Treatment of melanoma skin cancer

  https://www.cancer.org.nz/cancer/types-of-cancer/melanoma-of-the-skin/treatment-of-melanoma/

  Radiation treatment is commonly used for advanced melanoma to relieve symptoms such as pain or swelling. […] Chemotherapy can be given before or after surgery and is usually given by injecting the medication into a vein (IV treatment). […] Chemotherapy is occasionally used as palliative treatment for melanoma that cannot be treated by other methods. […] Immunotherapy is a treatment that boosts the body’s own immune system to fight cancer. […] The medications Keytruda (Pembrolizumab) and Opdivo (Nivolumab) are treatments that allow the T-cell to stay active (turned on) to fight melanoma cells. […] There have been many recent advances in melanoma treatment, and more are expected soon. […] Palliative care aims to improve your quality of life. […] Speak with your treatment team about palliative care options for you and your family/whānau.

• #58 Melanoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/melanoma/diagnosis-treatment/drc-20374888

  Chemotherapy might be an option to help control melanoma that doesn’t respond to other treatments. It might be used when immunotherapy or targeted therapy aren’t helping. […] Sometimes chemotherapy can be given in a vein in your arm or leg in a procedure called isolated limb perfusion. During this procedure, blood in your arm or leg isn’t allowed to travel to other areas of your body for a short time. This helps keep the chemotherapy medicines near the melanoma and doesn’t affect other parts of your body.

• #59 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  For patients with stage III in-transit disease, primary treatment options include the following: Complete resection (preferred, if feasible) […] SLNB for resectable disease […] Hyperthermic perfusion/infusion with melphalan for localized multiple lesions in a single extremity or recurrent lesions in a single limb […] Talimogene laherparepvec is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrence after initial surgery […] Optimal regimens and durations for neoadjuvant systemic therapy are not well established, but the following are typically used: Pembrolizumab 200 mg IV q3wk three doses or Ipilimumab 1 mg/kg IV plus nivolumab 3 mg/kg q3wk for two cycles […] Combination treatment provides better response and control of the disease and is often used in patients with advanced or metastatic disease who clinically are able to tolerate this approach

• #60 Treatment of Metastatic Melanoma: An Overview

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2737459/

  High-dose interleukin-2 (HD IL-2 [Proleukin]), approved by the FDA in 1998 for metastatic melanoma, benefits a small subset of patients. […] Systemic therapy is the mainstay of therapy for most patients with stage IV melanoma. […] Cytotoxic chemotherapy has been used for the treatment of metastatic melanoma for over 3 decades. […] Dacarbazine is typically administered intravenously at a dose of 150 to 200 mg/m2/d for 5 days or at a single dose of 800 to 1,000 mg/m2, with doses repeated every 3 to 4 weeks. […] Despite its modest efficacy and lack of data for survival benefit, dacarbazine continues to be the standard treatment of metastatic melanoma. […] The modest antitumor activity of the chemotherapeutic agents mentioned above led to investigation of combinations of these agents to improve outcomes.

• #61 Interferon Treatment for Melanoma – Skin Cancer Medication Uses & Side Effects

  https://www.webmd.com/melanoma-skin-cancer/what-drugs-treat-melanoma

  If youre having surgery to remove a melanoma, your doctors might suggest interferon alfa (Intron A, Roferon-A) afterward to help keep the melanoma from coming back. […] This group of drugs goes after the melanoma cells. Theyre different from chemotherapy drugs, which attack all cells that divide fast, not just cancer cells. […] Your doctor will only prescribe them if your melanoma cant be removed with surgery and you have whats known as a BRAF gene mutation. About 40% to 60% of melanomas have this mutation. […] The medications do help shrink and slow tumor growth for a period of time. […] Chemotherapy drugs are used to treat advanced melanoma. Its often the last choice after immunotherapy and targeted drugs because it doesnt work as well on melanoma as it does on other types of cancer. […] Your doctor might give you a combination of these, or they may use them with immunotherapy drugs like interferon-alpha.

• #62 Treatment of Metastatic Melanoma: An Overview

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2737459/

  The 10-year survival rate for patients with metastatic melanoma is less than 10%. […] Although surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy is the mainstay of treatment for most patients. […] Single-agent chemotherapy is well tolerated but is associated with response rates of only 5% to 20%. […] Combination chemotherapy and biochemotherapy may improve objective response rates but do not extend survival and are associated with greater toxicity. […] Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients. […] More than 3 decades after its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be the standard of care for most patients with this disease.

• #63 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  The type of treatment(s) your doctor recommends will depend mainly on the stage and location of the melanoma. […] Stage 0 melanoma (melanoma in situ) has not grown deeper than the top layer of the skin (the epidermis). It is usually treated by surgery (wide excision) to remove the melanoma and a small margin of normal skin around it. […] Some doctors may consider the use of imiquimod cream (Zyclara) or radiation therapy after surgery if not all the cancer cells can be removed for some reason, although not all doctors agree with this. […] Stage I melanomas have grown into deeper layers of the skin, but they haven’t grown beyond the area where they started. […] These cancers are typically treated by wide excision (surgery to remove the tumor as well as a margin of normal skin around it).

• #64 Melanoma Treatment – NCI

  https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq

  Melanoma is a disease in which malignant (cancer) cells form in melanocytes (cells that color the skin). […] There are different types of treatment for people with melanoma. […] The following types of treatment are used: Surgery, Chemotherapy, Radiation therapy, Immunotherapy, Targeted therapy. […] Treatment of stage 0 is usually surgery to remove the area of abnormal cells and a small amount of normal tissue around it. […] Treatment of stage I melanoma is usually surgery to remove the tumor and some of the normal tissue around it, with or without lymph node mapping and sentinel lymph node biopsy. […] Treatment of stage II melanoma may include: surgery to remove the tumor and some of the normal tissue around it, with lymph node mapping and sentinel lymph node biopsy. If cancer is found in the sentinel lymph node, more lymph nodes may be removed.

• #65 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Some doctors may recommend a sentinel lymph node biopsy (SLNB) to look for cancer in nearby lymph nodes, especially if the melanoma is stage IB or has other traits that make it more likely to have spread. […] If the SLNB does not find cancer cells in the lymph nodes, then no further treatment is needed, although close follow-up is still important. […] If cancer cells are found on the SLNB (which changes the cancer stage to stage III), a lymph node dissection (removal of all lymph nodes near the cancer) might be recommended. […] For certain stage II melanomas, the immune checkpoint inhibitor pembrolizumab (Keytruda) might be given after surgery to help reduce the risk of the cancer returning. […] Surgical treatment for stage III melanoma usually requires wide excision of the primary tumor as in earlier stages, along with a lymph node dissection (where all the nearby lymph nodes are surgically removed).

• #66 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  Treatment protocols for malignant melanoma are provided below, including recommendations for the following: […] For patients with stage 0 and stage IA melanoma (0.8 mm thick, no ulceration) wide-excision surgery is recommended as primary treatment […] For patients with stage IA with one or more adverse features (eg, very high mitotic index 2/mm2, particularly in a young patient; lymphovascular invasion), discuss and consider sentinel lymph node biopsy (SLNB) in addition to wide-excision surgery […] Surgery is recommended for stage IIB or IIC; also discuss or offer SLNB […] If SLNB is performed and is node positive, then complete dissection of nodal basin should be performed […] Alternative recommendations are observation; clinical trial enrollment; or pembrolizumab, nivolumab, and/or primary tumor site radiation therapy to reduce local recurrence

• #67 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  Patients who are younger, female, and who have melanomas on their extremities generally have better prognoses. […] Long-term follow-up is important for detection of recurrence, managing long-term effects, and surveillance of new lesions. […] Surgical excision remains the primary modality for treating localized melanoma. […] Localized melanoma is excised with margins proportional to the microstage of the primary lesion. […] Lymphatic mapping and SLNB should be considered to assess the presence of occult metastasis in the regional lymph nodes of patients with primary tumors measuring at least 0.8 mm thick with clinically negative nodes. […] Adjuvant therapy options for patients at high risk of recurrence after complete resection include checkpoint inhibitors and combination signal transduction inhibitor therapy.

• #68 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Some doctors may recommend a sentinel lymph node biopsy (SLNB) to look for cancer in nearby lymph nodes, especially if the melanoma is stage IB or has other traits that make it more likely to have spread. […] If the SLNB does not find cancer cells in the lymph nodes, then no further treatment is needed, although close follow-up is still important. […] If cancer cells are found on the SLNB (which changes the cancer stage to stage III), a lymph node dissection (removal of all lymph nodes near the cancer) might be recommended. […] For certain stage II melanomas, the immune checkpoint inhibitor pembrolizumab (Keytruda) might be given after surgery to help reduce the risk of the cancer returning. […] Surgical treatment for stage III melanoma usually requires wide excision of the primary tumor as in earlier stages, along with a lymph node dissection (where all the nearby lymph nodes are surgically removed).

• #69 Melanoma Treatment – NCI

  https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq

  Treatment of stage III melanoma that can be removed by surgery may include: immunotherapy with pembrolizumab before surgery, surgery to remove the tumor and some of the normal tissue around it, with or without skin grafting to cover the wound caused by surgery. […] Treatment of stage III melanoma that cannot be removed by surgery, stage IV melanoma, and recurrent melanoma may include: immunotherapy with pembrolizumab, nivolumab, ipilimumab, interleukin-2 (IL-2), nivolumab and relatimab, or atezolizumab, given alone or in combination. […] Treatment for melanoma may cause side effects. […] Follow-up care may be needed.

• #70 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Some doctors may recommend a sentinel lymph node biopsy (SLNB) to look for cancer in nearby lymph nodes, especially if the melanoma is stage IB or has other traits that make it more likely to have spread. […] If the SLNB does not find cancer cells in the lymph nodes, then no further treatment is needed, although close follow-up is still important. […] If cancer cells are found on the SLNB (which changes the cancer stage to stage III), a lymph node dissection (removal of all lymph nodes near the cancer) might be recommended. […] For certain stage II melanomas, the immune checkpoint inhibitor pembrolizumab (Keytruda) might be given after surgery to help reduce the risk of the cancer returning. […] Surgical treatment for stage III melanoma usually requires wide excision of the primary tumor as in earlier stages, along with a lymph node dissection (where all the nearby lymph nodes are surgically removed).

• #71 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Some doctors may recommend a sentinel lymph node biopsy (SLNB) to look for cancer in nearby lymph nodes, especially if the melanoma is stage IB or has other traits that make it more likely to have spread. […] If the SLNB does not find cancer cells in the lymph nodes, then no further treatment is needed, although close follow-up is still important. […] If cancer cells are found on the SLNB (which changes the cancer stage to stage III), a lymph node dissection (removal of all lymph nodes near the cancer) might be recommended. […] For certain stage II melanomas, the immune checkpoint inhibitor pembrolizumab (Keytruda) might be given after surgery to help reduce the risk of the cancer returning. […] Surgical treatment for stage III melanoma usually requires wide excision of the primary tumor as in earlier stages, along with a lymph node dissection (where all the nearby lymph nodes are surgically removed).

• #72 Treatment Option for Stage 3 Melanoma | KEYTRUDA® (pembrolizumab)

  https://www.keytruda.com/melanoma/melanoma-treatment-stage-3/

  KEYTRUDA may help prevent melanoma from returning or spreading to other parts of the body after surgery to remove it and the lymph nodes that contain cancer. KEYTRUDA is an FDA-approved immunotherapy that may be used to prevent melanoma from coming back or spreading to other parts of the body after stage 3 melanoma and the lymph nodes that contain cancer have been removed by surgery. […] Your doctor may recommend treatment after surgery that may help prevent cancer from coming back or spreading to other parts of the body. […] It may be used in adults and children 12 years of age and older with stage IIB, stage IIC, or stage III melanoma, to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

• #73 Adjuvant Therapy for Treatment of Melanoma

  https://www.curemelanoma.org/patient-eng/melanoma-treatment/adjuvant-therapy

  Adjuvant therapy is sometimes used after surgery to reduce the risk of melanoma returning. […] Adjuvant therapy is often recommended for patients with high-risk melanoma following surgery. […] The stage of your melanoma at diagnosis helps to determine your risk for recurrence after surgery. […] Patients with Stage 2B and 2C melanoma should discuss possible benefits and risks of adjuvant therapy with their doctor. […] Adjuvant therapy is usually not recommended for patients with Stage IIIA melanoma. […] Patients in these groups have a high risk for recurrence and adjuvant therapy is often recommended if they have melanoma that is deeper or thicker (more than 4 mm thick) at the primary site or involves nearby lymph nodes. […] Studies have shown that adjuvant therapy for melanoma can reduce the risk of your melanoma returning following surgery by up to 50%.

• #74 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  The reason for offering adjuvant treatment is to try to kill these cancer cells and increase the chance of cure after surgery. […] Adjuvant therapy usually lasts for 1 year but could be less if you have had neoadjuvant treatment before your surgery. […] Adjuvant therapy can reduce the risk of your melanoma coming back (recurrence) after surgery. […] As with all drug treatments, some people will experience side effects with adjuvant therapy, but these do not affect everyone. […] Some patients who have had surgery for Stage 2B or 2C melanoma may be offered adjuvant immunotherapy to reduce their chance of further problems from the melanoma. […] Pembrolizumab is currently the only treatment approved for stage 2B or 2C melanoma, however, there are ongoing clinical trials looking at other treatments.

• #75 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Some doctors may recommend a sentinel lymph node biopsy (SLNB) to look for cancer in nearby lymph nodes, especially if the melanoma is stage IB or has other traits that make it more likely to have spread. […] If the SLNB does not find cancer cells in the lymph nodes, then no further treatment is needed, although close follow-up is still important. […] If cancer cells are found on the SLNB (which changes the cancer stage to stage III), a lymph node dissection (removal of all lymph nodes near the cancer) might be recommended. […] For certain stage II melanomas, the immune checkpoint inhibitor pembrolizumab (Keytruda) might be given after surgery to help reduce the risk of the cancer returning. […] Surgical treatment for stage III melanoma usually requires wide excision of the primary tumor as in earlier stages, along with a lymph node dissection (where all the nearby lymph nodes are surgically removed).

• #76 Melanoma Treatment (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65950/

  Treatment of stage II melanoma may include: surgery to remove the tumor and some of the normal tissue around it, with lymph node mapping and sentinel lymph node biopsy. […] Treatment of stage III melanoma that can be removed by surgery may include: immunotherapy with pembrolizumab before surgery, surgery to remove the tumor and some of the normal tissue around it, with or without skin grafting to cover the wound caused by surgery. […] Treatment of stage III melanoma that cannot be removed by surgery, stage IV melanoma, and recurrent melanoma may include: immunotherapy with pembrolizumab, nivolumab, ipilimumab, interleukin-2 (IL-2), nivolumab and relatimab, or atezolizumab, given alone or in combination.

• #77 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  If you have been diagnosed with stage 3A, 3B, 3C or 3D melanoma you may be offered adjuvant immunotherapy treatment (pembrolizumab or nivolumab), or BRAF-targeted therapy (dabrafenib and trametinib) if you have a faulty BRAF gene. […] If you have completely resected stage 4 melanoma you may be offered adjuvant immunotherapy treatment. […] Targeted treatments for stage 3 melanoma can be offered if your melanoma contains a BRAF mutation. […] BRAF-targeted treatment is taken twice a day by mouth at home for up to 1 year. […] Immunotherapy uses our immune system to fight cancer. […] It works by helping the immune system recognise and attack cancer cells. […] Immunotherapy treatment is given for up to 1 year and is suitable for patients with BRAF-positive or BRAF-negative melanoma.

• #78 Adjuvant Therapy for Treatment of Melanoma

  https://www.curemelanoma.org/patient-eng/melanoma-treatment/adjuvant-therapy

  Opdivo (nivolumab) and Keytruda (pembrolizumab) are considered the preferred agents for adjuvant therapy in melanoma. […] Adjuvant Therapy Clinical Trials test treatments or methods that have not yet been approved by the FDA. […] Yervoy (ipilimumab) is approved as a single agent for adjuvant therapy in melanoma, but it has largely been replaced by nivolumab or pembrolizumab. […] In rare circumstances, older therapies may still be used, particularly for patients at high risk for recurrence who cannot take newer immunotherapies due to other conditions or contraindication.

• #79 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  If you have been diagnosed with stage 3A, 3B, 3C or 3D melanoma you may be offered adjuvant immunotherapy treatment (pembrolizumab or nivolumab), or BRAF-targeted therapy (dabrafenib and trametinib) if you have a faulty BRAF gene. […] If you have completely resected stage 4 melanoma you may be offered adjuvant immunotherapy treatment. […] Targeted treatments for stage 3 melanoma can be offered if your melanoma contains a BRAF mutation. […] BRAF-targeted treatment is taken twice a day by mouth at home for up to 1 year. […] Immunotherapy uses our immune system to fight cancer. […] It works by helping the immune system recognise and attack cancer cells. […] Immunotherapy treatment is given for up to 1 year and is suitable for patients with BRAF-positive or BRAF-negative melanoma.

• #80 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  Pembrolizumab is indicated for adjuvant treatment of resected, high-risk stage III melanoma; level one evidence showed significantly prolonged 1-year recurrence-free survival with pembrolizumab (200 mg IV q3wk for 1 year) compared with placebo (75.4% vs 61%; P 0.001) […] Nivolumab is indicated for adjuvant treatment of resected stage III or IV melanoma; level one evidence shows that recurrence-free survival is better with nivolumab (3 mg/kg IV q2wk for 1 year) than with ipilimumab […] If BRAF V600 mutation positive, dabrafenib 150 mg PO BID plus trametinib 2 mg PO qd […] Ipilimumab is indicated for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes 1 mm who have undergone complete resection, including total lymphadenectomy; the recommended regimen is 10 mg/kg IV q3wk for 4 doses followed by 10 mg/kg q12wk for up to 3 years

• #81 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  Pembrolizumab 200 mg q3wk until disease progression or unacceptable toxicity […] Nivolumab 240 mg q2wk or 480 mg q4wk until disease progression or unacceptable toxicity […] For stage III (clinically positive nodes), surgical excision is recommended with complete lymph node dissection; adjuvant therapy includes clinical trials, observation, or biologic therapy; pembrolizumab or nivolumab are currently favored for biologic therapy, as they have a better toxicity profile than interferon or ipilumimab […] Consider radiation therapy to nodal basin for stage IIIC disease with multiple nodes involved or macroscopic extranodal extension […] Biologic therapy for stage III melanoma is selected on the basis of the toxicity profile and results of randomized trials […] PD-1 inhibitors are commonly used today rather than ipilumimab and interferon formulations due to lesser toxicity with these agents

• #82 Melanoma Treatment (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65950/

  Treatment of stage II melanoma may include: surgery to remove the tumor and some of the normal tissue around it, with lymph node mapping and sentinel lymph node biopsy. […] Treatment of stage III melanoma that can be removed by surgery may include: immunotherapy with pembrolizumab before surgery, surgery to remove the tumor and some of the normal tissue around it, with or without skin grafting to cover the wound caused by surgery. […] Treatment of stage III melanoma that cannot be removed by surgery, stage IV melanoma, and recurrent melanoma may include: immunotherapy with pembrolizumab, nivolumab, ipilimumab, interleukin-2 (IL-2), nivolumab and relatimab, or atezolizumab, given alone or in combination.

• #83 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  After surgery, (additional) adjuvant treatment with immune checkpoint inhibitors or with targeted therapy drugs (for cancers with BRAF gene changes) may help lower the risk of the melanoma coming back. […] Stage IV melanomas have already spread (metastasized) to other parts of the body, such as distant lymph nodes, areas of skin, or other organs. […] The treatment of widespread melanomas has changed in recent years as newer forms of immunotherapy and targeted drugs have been shown to be more effective than chemotherapy. […] Immunotherapy drugs called checkpoint inhibitors are often the first treatment. […] In about half of all melanomas, the cancer cells have BRAF gene changes. These melanomas often respond to treatment with targeted therapy drugs typically a combination of a BRAF inhibitor and a MEK inhibitor.

• #84 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) […] Treatment of metastatic melanoma focuses on: […] Drug treatments — There are three main categories of drug treatments: […] Immunotherapy – Drugs that stimulate or unleash your immune system to attack and kill the cancer cells […] Targeted therapy – Drugs that inhibit specific enzymes or molecules important to the cancer cells […] Chemotherapy – Drugs that stop or slow the growth of cancer cells by interfering with their ability to divide or reproduce themselves […] Advances in the use of immunotherapy and targeted therapy have improved survival for many people with melanoma. Most people will get immunotherapy as the first treatment. Targeted therapy, if a person is a candidate, is often used when the melanoma is no longer being controlled by immunotherapy. Although chemotherapy was widely used in the past, it now has a limited role for people whose disease can no longer be controlled with either immunotherapy or targeted therapy.

• #85 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Immunotherapy — Several different types of immunotherapy have been developed, the most important of which are checkpoint inhibitors (nivolumab [brand name: Opdivo], pembrolizumab [brand name: Keytruda], ipilimumab [brand name: Yervoy], and nivolumab-relatlimab [brand name: Opdualag]), which have replaced high-dose interleukin-2 (IL-2) […] Nivolumab and pembrolizumab — The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) unleash the body’s immune system to reject the melanoma. […] Treatment with nivolumab, pembrolizumab, or the combination of nivolumab plus ipilimumab may decrease the extent of your melanoma and help you live longer. […] Targeted therapy — About one-half of metastatic melanomas contain a specific mutation at a particular spot in one gene (BRAF) that causes the cell to make a particular protein that drives the growth of cancer cells.

• #86 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  For limited disease, resection is recommended, followed by nivolumab […] For patients who have unresectable or metastatic melanoma with BRAF V600E or V600K mutation: Trametinib 2 mg PO qd plus dabrafenib 150 mg PO BID for BRAF V600E or V600K mutations […] Pembrolizumab 200 mg IV q3wk over 30 min until disease progression or unacceptable toxicity; if BRAF V600 mutation positive, a BRAF inhibitor (dabrafenib, vemurafenib) […] Nivolumab 240 mg IV q2wk or 480 mg IV q4wk over 30 min until disease progression or unacceptable toxicity; if BRAF V600 mutation positive, a BRAF inhibitor […] Lifileucel is indicated for unresectable or metastatic melanoma in adults previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

• #87 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Immunotherapy — Several different types of immunotherapy have been developed, the most important of which are checkpoint inhibitors (nivolumab [brand name: Opdivo], pembrolizumab [brand name: Keytruda], ipilimumab [brand name: Yervoy], and nivolumab-relatlimab [brand name: Opdualag]), which have replaced high-dose interleukin-2 (IL-2) […] Nivolumab and pembrolizumab — The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) unleash the body’s immune system to reject the melanoma. […] Treatment with nivolumab, pembrolizumab, or the combination of nivolumab plus ipilimumab may decrease the extent of your melanoma and help you live longer. […] Targeted therapy — About one-half of metastatic melanomas contain a specific mutation at a particular spot in one gene (BRAF) that causes the cell to make a particular protein that drives the growth of cancer cells.

• #88 Targeted Drugs & Immunotherapy for Melanoma | NYU Langone Health

  https://nyulangone.org/conditions/melanoma/treatments/targeted-drugs-immunotherapy-for-melanoma

  Immunotherapies encourage the bodys immune system to attack cancer cells. […] About 11 percent of people with melanoma that has spread respond to this drug, meaning the tumor shrinks. […] People receive a combination of ipilimumab and nivolumab, monoclonal antibody medications that target a protein to improve the bodys immune response to melanoma by encouraging disease-fighting white blood cells, called T cells, to become more active. Melanoma shrinks in more than 50 percent of people given this combination of drugs. […] Doctors may prescribe another monoclonal antibody medication called pembrolizumab, which also binds to proteins on the surface of cancer cells, making them more vulnerable to T cell activity. […] Together, these immunotherapies can boost the immune system and make cancer cells more susceptible to a T cell attack.

• #89 FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma

  Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells. […] Amtagvi is a tumor-derived autologous T cell immunotherapy composed of a patients own T cells, a type of cell that helps the immune system fight cancer. […] Melanoma is a life-threatening cancer that can cause devastating impacts to affected individuals, with a significant risk of metastasizing and spreading to other areas in the body, said Nicole Verdun, M.D., director of the Office of Therapeutic Products in CBER. […] The safety and effectiveness of Amtagvi was evaluated in a global, multicenter, multicohort clinical study including adult patients with unresectable or metastatic melanoma who had previously been treated with at least one systemic therapy, including a PD-1 blocking antibody, and if positive for the BRAF V600 mutation, a BRAF inhibitor or BRAF inhibitor with an MEK inhibitor. Effectiveness was established based on objective response rate to treatment and duration of response.

• #90 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  For limited disease, resection is recommended, followed by nivolumab […] For patients who have unresectable or metastatic melanoma with BRAF V600E or V600K mutation: Trametinib 2 mg PO qd plus dabrafenib 150 mg PO BID for BRAF V600E or V600K mutations […] Pembrolizumab 200 mg IV q3wk over 30 min until disease progression or unacceptable toxicity; if BRAF V600 mutation positive, a BRAF inhibitor (dabrafenib, vemurafenib) […] Nivolumab 240 mg IV q2wk or 480 mg IV q4wk over 30 min until disease progression or unacceptable toxicity; if BRAF V600 mutation positive, a BRAF inhibitor […] Lifileucel is indicated for unresectable or metastatic melanoma in adults previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

• #91 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  Targeted therapy with vemurafenib plus cobimetinib, dabrafenib plus trametinib, or encorafenib and binimetinib has also been shown to improve overall survival in the majority of people whose tumors contain BRAFV600 mutations. […] In deciding what treatment is right for you, you and your family must consider the risks and benefits of each option according to your values and preferences.

• #92 Melanoma treatment options – MSCAN

  https://mscan.org.au/learning-hub/melanoma/melanoma-treatment-options/

  While historical options used in the treatment of melanoma were not very effective, modern drug therapies are known to be effective in a significant percentage of patients. Treatment can often involve more than one type of treatment. […] Targeted therapy is a type of treatment that uses drugs to identify and stop the action of molecules that are key to the growth of cancer cells. […] Current targeted therapy combinations approved for use in Australia include: Dabrafenib + trametinib (Also known as Tafinlar + Mekinist), Vemurafenib + cobimetinib (Also known as Zelboraf + Cotellic), Encorafenib + binimetinib (Also known as Braftovi + Mektovi). […] The immune system allows the body to distinguish its own healthy cells from abnormal or foreign cells and organisms. […] The main types of immunotherapy used to treat advanced melanoma include: Immune Checkpoint Inhibitors, Cellular Therapies.

• #93 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  These drugs prolong the time until there is disease growth and extend overall survival in people with BRAF-mutant melanoma. […] Chemotherapy — Chemotherapy uses medicines such as dacarbazine or temozolomide with or without cisplatin to stop or slow the growth of cancer cells by interfering with the ability of cancer cells to divide or reproduce. […] Surgery — Surgery may be recommended if melanoma has spread to only one or a very limited number of sites. […] Radiation therapy — Melanoma frequently spreads to the brain. Treatment options may include surgery, immunotherapy, or radiation. […] END-OF-LIFE CARE […] Significant progress has been made in the treatment of metastatic melanoma. […] The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) and the combinations of nivolumab plus ipilimumab or nivolumab plus relatlimab are effective for controlling metastatic melanoma and prolonging life.

• #94 Treatments for metastatic melanoma skin cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/melanoma-skin/treatment/metastatic

  Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them to stop the growth and spread of cancer. Targeted therapy is usually offered for unresectable locoregional or metastatic melanoma with certain gene changes (mutations), including mutations in the BRAF gene. […] Surgery is rarely used to treat metastatic melanoma. You may be offered surgery if cancer is only in: 1 or a few small areas on or just under the skin, 1 group of lymph nodes, a lung, the liver, the brain or the small intestine. […] Radiation therapy uses high-energy rays or particles to destroy cancer cells. You may be offered radiation therapy for metastatic melanoma. It is also used as a palliative treatment to control symptoms from metastases. […] Chemotherapy uses drugs to destroy cancer cells. It may be offered to control symptoms of metastatic melanoma (called palliative chemotherapy). It may also be used to treat metastatic melanoma if other treatments haven’t worked.

• #95 Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics

  These drugs prolong the time until there is disease growth and extend overall survival in people with BRAF-mutant melanoma. […] Chemotherapy — Chemotherapy uses medicines such as dacarbazine or temozolomide with or without cisplatin to stop or slow the growth of cancer cells by interfering with the ability of cancer cells to divide or reproduce. […] Surgery — Surgery may be recommended if melanoma has spread to only one or a very limited number of sites. […] Radiation therapy — Melanoma frequently spreads to the brain. Treatment options may include surgery, immunotherapy, or radiation. […] END-OF-LIFE CARE […] Significant progress has been made in the treatment of metastatic melanoma. […] The anti-programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab, pembrolizumab) and the combinations of nivolumab plus ipilimumab or nivolumab plus relatlimab are effective for controlling metastatic melanoma and prolonging life.

• #96 Treatments for metastatic melanoma skin cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/melanoma-skin/treatment/metastatic

  Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them to stop the growth and spread of cancer. Targeted therapy is usually offered for unresectable locoregional or metastatic melanoma with certain gene changes (mutations), including mutations in the BRAF gene. […] Surgery is rarely used to treat metastatic melanoma. You may be offered surgery if cancer is only in: 1 or a few small areas on or just under the skin, 1 group of lymph nodes, a lung, the liver, the brain or the small intestine. […] Radiation therapy uses high-energy rays or particles to destroy cancer cells. You may be offered radiation therapy for metastatic melanoma. It is also used as a palliative treatment to control symptoms from metastases. […] Chemotherapy uses drugs to destroy cancer cells. It may be offered to control symptoms of metastatic melanoma (called palliative chemotherapy). It may also be used to treat metastatic melanoma if other treatments haven’t worked.

• #97 Treatment of Melanoma by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/by-stage.html

  Chemotherapy (chemo) can help some people with stage IV melanoma, but other treatments are usually tried first. […] Because stage IV melanoma is often hard to cure with current treatments, people may want to think about taking part in a clinical trial. […] Treatment of melanoma that comes back after initial treatment depends on where in the body the melanoma is, what treatments a person has already had, the person’s overall health and preferences, and other factors. […] If melanoma recurs in nearby lymph vessels in or just under the skin (known as in-transit recurrence), it should be removed with surgery, if possible. […] Lymph node recurrence is typically treated by lymph node dissection if it can be done, sometimes followed by adjuvant (additional) treatments such as radiation therapy and/or immunotherapy or targeted therapy (for cancers with BRAF gene changes).

• #98 Treatment of Metastatic Melanoma: An Overview

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2737459/

  The combination of cisplatin, dacarbazine, BCNU, and tamoxifen (CDBT), also known as the Dartmouth regimen, was initially reported to have an ORR of 55%. […] However, a phase III multicenter trial that randomized 240 patients to the CDBT regimen vs dacarbazine monotherapy did not show a statistically significant benefit in favor of the combination. […] Cytotoxic chemotherapy may have a palliative benefit in some patients with metastatic melanoma, but it usually does not lead to durable responses and has not been proven to have a survival benefit. […] High-dose bolus IL-2 (HD IL-2) was approved by the FDA in 1998 for the treatment of metastatic melanoma due to the potential for durable complete responses in a small number of patients. […] To summarize, HD IL-2 may lead to durable complete responses in a subset of patients and should be considered in patients who are likely to tolerate it.

• #99 Immunotherapy and cell therapy expand treatment possibilities for melanoma patients | Stanford Cancer Institute

  https://med.stanford.edu/cancer/about/news/melanoma.html

  Immunotherapy and cell therapy expand treatment possibilities for melanoma patients […] Melanoma is the deadliest form of skin cancer, despite only accounting for 1% of all skin cancers. […] To learn more about current melanoma treatment and advances in treatment, we talked with SCI member Allison Betof Warner, MD, PhD, leader of Stanfords Melanoma Cutaneous Oncology Clinical Research Group. […] Stage 4 melanoma survival rate has drastically improved with immunotherapy […] In the past, the survival outcomes after a stage 4 melanoma diagnosis used to be measured in months, but now more than half of patients live for five years or more after being diagnosed. This is because the standard of care has shifted to immunotherapy, which is exceptionally effective for melanoma in part due to the high tumor mutation burden caused by UV damage.

• #100 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Significant progress has been made in the last few decades in melanoma therapeutics, most notably in targeted therapy and immunotherapy. These approaches have greatly improved treatment response outcomes; however, they remain limited in their abilities to hinder disease progression due, in part, to the onset of acquired resistance. In parallel, intrinsic resistance to therapy remains an issue to be resolved. In this review, we summarize currently available therapeutic options for melanoma treatment and focus on possible mechanisms that drive therapeutic resistance. A better understanding of therapy resistance will provide improved rational strategies to overcome these obstacles. […] Surgical tumor removal has been the standard of care for patients with primary melanoma. Radiation therapy, which is common for many other cancer types, has not gained widespread use in melanoma, as skin tumors are usually radioresistant. Instead, therapeutic agent administration is a more likely treatment option for most patients. However, radiotherapy remains an option for patients with inoperable tumors, as well as imiquimod cream, a local immunomodulator prescribed to some patients with early-stage melanoma.

• #101 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  Melanoma treatment […] Neoadjuvant therapy is any treatment that is given before the complete surgical removal (resection) of a melanoma. […] The main aim of neoadjuvant therapy is to make surgery to remove the melanoma easier. Neoadjuvant therapy can shrink the size of the melanoma and therefore it should be easier to remove all of it. […] Neoadjuvant therapy may also mean that some people don’t need adjuvant therapy (after surgery to remove the melanoma), depending on if the doctors think that all the melanoma cells have been removed by neoadjuvant treatment and surgery. […] Adjuvant therapy refers to any extra treatment that is given after the complete surgical removal of a cancer (a melanoma in this case). […] The aim of the surgery is to cure you. However, even if your surgery was successful at removing all visible melanoma, invisible cancer cells sometimes remain.

• #102 Treatment for Early Melanoma | Cancer Council NSW

  https://www.cancercouncil.com.au/melanoma/treatment/

  Learn about the best treatment for early melanoma, including the importance of surgery and potential neoadjuvant options. […] Surgery is the most common treatment for melanoma that is found early (stages 0–2 or localised melanoma). If found early, 90% of melanomas can be cured with surgery alone. […] If the risk of the melanoma spreading is high or it has spread to nearby lymph nodes or tissues (stage 3 or regional melanoma), treatment may also include removing lymph nodes and additional (adjuvant) treatments. […] Your doctor may suggest you have drug treatment before surgery (neoadjuvant treatment).

• #103 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  Melanoma treatment […] Neoadjuvant therapy is any treatment that is given before the complete surgical removal (resection) of a melanoma. […] The main aim of neoadjuvant therapy is to make surgery to remove the melanoma easier. Neoadjuvant therapy can shrink the size of the melanoma and therefore it should be easier to remove all of it. […] Neoadjuvant therapy may also mean that some people don’t need adjuvant therapy (after surgery to remove the melanoma), depending on if the doctors think that all the melanoma cells have been removed by neoadjuvant treatment and surgery. […] Adjuvant therapy refers to any extra treatment that is given after the complete surgical removal of a cancer (a melanoma in this case). […] The aim of the surgery is to cure you. However, even if your surgery was successful at removing all visible melanoma, invisible cancer cells sometimes remain.

• #104 Adjuvant and Neoadjuvant treatment for melanoma – Melanoma Focus

  https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/adjuvant-treatment-for-melanoma/

  Melanoma treatment […] Neoadjuvant therapy is any treatment that is given before the complete surgical removal (resection) of a melanoma. […] The main aim of neoadjuvant therapy is to make surgery to remove the melanoma easier. Neoadjuvant therapy can shrink the size of the melanoma and therefore it should be easier to remove all of it. […] Neoadjuvant therapy may also mean that some people don’t need adjuvant therapy (after surgery to remove the melanoma), depending on if the doctors think that all the melanoma cells have been removed by neoadjuvant treatment and surgery. […] Adjuvant therapy refers to any extra treatment that is given after the complete surgical removal of a cancer (a melanoma in this case). […] The aim of the surgery is to cure you. However, even if your surgery was successful at removing all visible melanoma, invisible cancer cells sometimes remain.

• #105 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  For patients with stage III in-transit disease, primary treatment options include the following: Complete resection (preferred, if feasible) […] SLNB for resectable disease […] Hyperthermic perfusion/infusion with melphalan for localized multiple lesions in a single extremity or recurrent lesions in a single limb […] Talimogene laherparepvec is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrence after initial surgery […] Optimal regimens and durations for neoadjuvant systemic therapy are not well established, but the following are typically used: Pembrolizumab 200 mg IV q3wk three doses or Ipilimumab 1 mg/kg IV plus nivolumab 3 mg/kg q3wk for two cycles […] Combination treatment provides better response and control of the disease and is often used in patients with advanced or metastatic disease who clinically are able to tolerate this approach

• #106 Malignant Melanoma Treatment Protocols: Treatment Protocols

  https://emedicine.medscape.com/article/2006810-overview

  For patients with stage III in-transit disease, primary treatment options include the following: Complete resection (preferred, if feasible) […] SLNB for resectable disease […] Hyperthermic perfusion/infusion with melphalan for localized multiple lesions in a single extremity or recurrent lesions in a single limb […] Talimogene laherparepvec is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrence after initial surgery […] Optimal regimens and durations for neoadjuvant systemic therapy are not well established, but the following are typically used: Pembrolizumab 200 mg IV q3wk three doses or Ipilimumab 1 mg/kg IV plus nivolumab 3 mg/kg q3wk for two cycles […] Combination treatment provides better response and control of the disease and is often used in patients with advanced or metastatic disease who clinically are able to tolerate this approach

• #107 Melanoma

  https://www.cancervic.org.au/cancer-information/types-of-cancer/melanoma/treatment_for_melanoma.html

  Surgery is the most common treatment for melanoma that is found early (stages 02 or localised melanoma). If found early, 90% of melanomas can be cured with surgery alone. […] If the risk of the melanoma spreading is high or it has spread to nearby lymph nodes or tissues (stage 3 or regional melanoma), treatment may also include removing lymph nodes and additional (adjuvant) treatments. […] Your doctor may suggest you have drug treatment before surgery (neoadjuvant treatment). […] A wide local excision is often performed as a day procedure, so you can go home soon after the surgery if there are no complications. […] If the melanoma is thicker than 1 mm or is considered to have a high risk of spreading to the lymph nodes, the doctor will discuss the risks and benefits of having a sentinel lymph node biopsy.

• #108 Treating Melanoma Skin Cancer | How Is Melanoma Treated? | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating.html

  If you’ve been diagnosed with melanoma, your treatment team will discuss your treatment options with you. It’s important to weigh the benefits of each treatment option against the possible risks and side effects. […] Based on the stage of the cancer and other factors, your treatment options might include: Surgery for Melanoma Skin Cancer, Immunotherapy for Melanoma Skin Cancer, Targeted Therapy Drugs for Melanoma Skin Cancer, Chemotherapy for Melanoma Skin Cancer, Radiation Therapy for Melanoma Skin Cancer. […] Early-stage melanomas can often be treated with surgery alone, but more advanced cancers often require other treatments. Sometimes more than one type of treatment is used. […] Depending on your situation, you may have different types of doctors on your treatment team. These doctors may include: A dermatologist: a doctor who treats diseases of the skin, A surgical oncologist (or oncologic surgeon): a doctor who uses surgery to treat cancer, A medical oncologist: a doctor who treats cancer with medicines such as chemotherapy, immunotherapy, or targeted therapy, A radiation oncologist: a doctor who treats cancer with radiation therapy.

• #109 A Review of Current and Pipeline Drugs for Treatment of Melanoma

  https://www.mdpi.com/1424-8247/17/2/214

  There have been significant advancements in melanoma treatment in the past few decades. Although the incidence of melanoma cases continues to increase, mortality from advanced melanoma has decreased in the past decade given the recent advances in treatment. The known genetic drivers of melanoma include B-raf proto-oncogene (BRAF), neurofibromin 1 (NF1), and NRAS mutations. While standard therapies have traditionally included surgery, radiation therapy, and systemic chemotherapy, the development of targeted therapy and immunotherapy has revolutionized the management of melanoma. In particular, advanced melanoma treatment often requires a multidisciplinary approach with combination therapies to achieve better responses. Combination approaches using different treatment modalities, such as targeted therapy and immunotherapy, have demonstrated synergistic effects and improved outcomes in select patients.

• #110 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  The FDA approved IL-2 in 1998 because of durable complete response rates in a minority of patients (6%-7%) with previously treated metastatic melanoma in eight phase I and II studies. […] The combination of antiPD-1 and antiCTLA-4 immunotherapies (nivolumab and ipilimumab) also prolongs PFS and OS compared with ipilimumab, but the combination is associated with significant toxicity. […] The efficacy seen with immunotherapy is independent of BRAF variant status. […] Combinations of BRAF and MEK inhibitors have consistently shown superior efficacy compared with BRAF monotherapy.

• #111 Targeted therapy for melanoma | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/targeted-therapy-for-melanoma

  Targeted therapy drugs target something in or around the cancer cell that is helping it grow and survive. […] You only have targeted therapy to treat melanoma if tests show that the cancer cells have a change (mutation) in a gene called BRAF. This treatment has not been shown to be useful or safe unless the cancer cells have this change. […] You usually have 2 targeted therapy drugs in combination to treat melanoma. […] These drugs are also called cancer growth inhibitors. Each combination includes a drug called a braf inhibitor. The drugs block the signals that tell cells in the body to develop and divide. By blocking the signals, these drugs may stop cancer cells from developing or dividing. […] Sometimes, dabrafenib and trametinib are used after surgery to reduce the risk of melanoma coming back. This is called adjuvant treatment. These drugs are used to treat melanoma if it cannot be removed with surgery or has spread (advanced melanoma).

• #112 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  Large randomized trials with nivolumab and pembrolizumab and with combination signal transduction inhibitors (dabrafenib plus trametinib) have shown a clinically significant impact on relapse-free survival (RFS). […] Treatment options for patients with metastatic melanoma have rapidly expanded over the last decade. […] Pembrolizumab, nivolumab, ipilimumab, and relatlimab (in a fixed-dose formulation with nivolumab) are checkpoint inhibitors approved by the FDA. […] Studies indicate that both BRAF and MEK inhibitors can significantly impact the natural history of melanoma, although they do not appear to be curative as single agents. […] The combination of an antiprogrammed death-1 (PD-1) antibody and an anticytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody (nivolumab and ipilimumab) has prolonged progression-free survival (PFS) and overall survival (OS) compared with ipilimumab monotherapy.

• #113 Targeted Drugs & Immunotherapy for Melanoma | NYU Langone Health

  https://nyulangone.org/conditions/melanoma/treatments/targeted-drugs-immunotherapy-for-melanoma

  Immunotherapies encourage the bodys immune system to attack cancer cells. […] About 11 percent of people with melanoma that has spread respond to this drug, meaning the tumor shrinks. […] People receive a combination of ipilimumab and nivolumab, monoclonal antibody medications that target a protein to improve the bodys immune response to melanoma by encouraging disease-fighting white blood cells, called T cells, to become more active. Melanoma shrinks in more than 50 percent of people given this combination of drugs. […] Doctors may prescribe another monoclonal antibody medication called pembrolizumab, which also binds to proteins on the surface of cancer cells, making them more vulnerable to T cell activity. […] Together, these immunotherapies can boost the immune system and make cancer cells more susceptible to a T cell attack.

• #114 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Treatment with dacarbazine, a chemotherapeutic agent that was introduced in the 1970s, was the standard of care for melanoma patients until targeted therapy was introduced in 2011. Dacarbazine alkylates DNA non-specifically to block DNA replication. The rate of objective tumor responses in patients on dacarbazine ranged from 13 to 20%, with nearly all responses being partial. In addition, dacarbazine caused severe adverse effects (AE) in patients. […] BRAF is the most commonly mutated gene in melanoma, and it is therefore an attractive candidate for targeted therapy. One of the first inhibitors developed against mutated BRAF was sorafenib, which is a multikinase inhibitor that targets CRAF, both wild-type and mutant BRAF, and multiple receptor tyrosine kinases (RTKs). However, the efficacy of sorafenib was limited both as a single agent and in combination with chemotherapeutics, likely due to its weak affinity for BRAF. As a result, inhibitors that could bind specifically to mutated BRAF were developed, such as vemurafenib, dabrafenib and encorafenib. These inhibitors bind to the ATP-binding pocket of BRAF with increased affinity for BRAF V600E mutation which enhances their selectivity. They demonstrated increased efficacy over chemotherapeutic agents with a better dose-dependent tumor inhibition in preclinical studies, a higher rate of objective responses (OR) and improved overall survival (OS) in clinical trials. Despite the improved efficacy of BRAF inhibitors (BRAFi) over chemotherapy, in most cases disease progression occurs after 6–7 months of treatment due to acquired resistance. The molecular mechanism underlying this induced resistance is often the reactivation of MAPK signaling through initiation of the MEK cascade; this will be discussed in detail later in the review.

• #115 Adjuvant therapies for melanoma

  https://dermnetnz.org/topics/adjuvant-therapies-for-melanoma

  Local control of melanoma may be enhanced by adjuvant radiotherapy if the risk of local recurrence remains unacceptably high after surgical excision such as with: Inadequate wide excision margins, often due to anatomical or cosmetic constraints around the eye/conjunctiva, nose, lips, or ears, Satellite lesions, Neurotropism (perineural invasion) on histology, Desmoplastic melanoma, due to its tendency for local recurrence. […] Although randomised controlled trials have not evaluated the benefit of adjuvant radiotherapy, several large observational cohorts have reported positive results with 50-85% improvement in risk of local recurrence. Possible evidence was also observed for decreased nodal recurrence. […] The local inflammatory effects resulting from radiation therapy may provide a synergistic boost to the efficacy of immunotherapy. Further research is underway to evaluate its benefits.

• #116 Treating Melanoma Skin Cancer | How Is Melanoma Treated? | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating.html

  Its important to discuss all of your treatment options as well as their possible side effects with your treatment team to help make the decision that best fits your needs. […] Clinical trials are carefully controlled research studies that are done to get a closer look at promising new treatments or procedures. Clinical trials are one way to get state-of-the-art cancer treatment. […] You may hear about alternative or complementary methods to relieve symptoms or treat your cancer that your doctors havent mentioned. […] Be sure to talk to your cancer care team about any method you are thinking about using. They can help you learn what is known (or not known) about the method, which can help you make an informed decision. […] Whether you are thinking about treatment, getting treatment, or not being treated at all, you can still get supportive care to help with pain or other symptoms.

• #117 Different Treatment Options for Melanoma Skin Cancer – MRA

  https://www.curemelanoma.org/patient-eng/melanoma-treatment

  Chemotherapy uses drugs to kill or slow down the growth of cancer cells. Chemotherapies are no longer often used to treat cutaneous melanoma due to the recent advances in immunotherapy and targeted therapies, but they are utilized in some cases where melanoma is resistant to these newer approaches. […] Adjuvant therapy is additional treatment given after the primary treatment for melanoma (usually surgery) to reduce the risk of the cancer returning. […] Cellular Therapy, also called Cell-based therapy, is a type of medical treatment that involves the use of living cells to treat or prevent diseases. It is a rapidly evolving field in medicine that holds great promise for various conditions, including the treatment of melanoma and other cancers. […] Before you start to make treatment decisions, you should get up to speed on all of your options including clinical trials. This is particularly important for patients with advanced stages of melanoma.

• #118 Targeted Drugs & Immunotherapy for Melanoma | NYU Langone Health

  https://nyulangone.org/conditions/melanoma/treatments/targeted-drugs-immunotherapy-for-melanoma

  At Perlmutter Cancer Center, people with advanced melanoma are usually considered for a clinical trial before they are given targeted medications or immunotherapies. Clinical trials offer people who have melanoma the chance to try combinations of newer medications, which may be more effective than standard treatment. […] Researchers are exploring new treatments for melanoma that has spread to the brain and new medications for melanoma that is resistant to BRAF inhibitor.

• #119 Cell Therapy is Now on The Table for Metastatic Melanoma – InventUMPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–button

  https://news.med.miami.edu/cell-therapy-on-the-table-for-metastatic-melanoma/

  “These are not easy treatments, but many patients do have great responses,” Dr. Lutzky said. […] Dr. Lutzky hopes to open enrollment for Sylvester’s participation in the phase 2 Iovance trial soon and enroll around 10 or more patients in the next year. This clinical trial will enroll patients with advanced melanoma whose previous treatments have failed. […] The trial will test a variation of TIL therapy in which the immune cells are genetically engineered in the lab to remove a gene called PD-1. […] Removing PD-1 from the lymphocytes may enhance their cancer-killing ability in the body, Dr. Lutzky said. Laboratory studies and an earlier stage clinical trial of these modified cells showed that they are just as active as the non-engineered lymphocytes. […] Before he joined Sylvester, Dr. Lutzky participated in clinical trials that led to FDA approval of another immunotherapy for metastatic melanoma, a checkpoint inhibitor called ipilimumab.

• #120 Immunotherapy and cell therapy expand treatment possibilities for melanoma patients | Stanford Cancer Institute

  https://med.stanford.edu/cancer/about/news/melanoma.html

  The trials have exploded in this space as weve found new treatment modalities. […] However, the majority of patients still dont have durable responses to immunotherapy. […] TIL therapy offers promising results for treating melanoma […] Tumor-infiltrating lymphocyte (TIL) therapy is a cell-based therapy where immune cells are surgically removed from the patients tumor, grown and expanded, and then given back to the patient by IV to kill tumor cells. […] The first major commercial TIL therapy paper, an update was published last year, showed that 31% of patients responded to TIL therapy, and more than half who responded saw their tumors continue to respond a year after this one-time treatment. […] TIL therapy was recently approved for cancer treatment in The Netherlands and is currently under review by the FDA. Researchers are hoping the therapy will be approved in the U.S. by the end of the year.

• #121 FDA Approved Drugs – AIM at Melanoma Foundation

  https://www.aimatmelanoma.org/fda-approved-drugs/

  What Drugs Are Used To Treat Melanoma? This page offers information on the various types of FDA-approved medications that doctors prescribe for treating individuals diagnosed with melanoma. Immunotherapy drugs are designed to boost the body’s immune system, helping it fight off cancer cells more effectively. Pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) are examples of immunotherapy drugs that have been approved by the FDA for treating melanoma. Targeted therapy drugs work by specifically targeting certain proteins or genes that play a role in the growth and spread of cancer cells. Examples of targeted therapy drugs used for melanoma treatment include vemurafenib (Zelboraf). […] Surgery is one of the treatment options for melanoma. Immunotherapy is another treatment option that helps the immune system fight cancer. Targeted therapy is also used to treat melanoma by targeting specific mutations in cancer cells. TIL Therapy is a type of immunotherapy that uses tumor-infiltrating lymphocytes to treat melanoma. Vaccines are being researched as a potential treatment for melanoma. Oncolytic Virus Therapy is another innovative approach being explored for melanoma treatment. Radiation Therapy may be used in certain cases of melanoma. FDA Approved Drugs are available for the treatment of melanoma. Support Tools for Treatment Decisions can help patients make informed choices about their treatment options. Life During Treatment can be challenging, and support is available for patients undergoing melanoma treatment.

• #122 A Review of Current and Pipeline Drugs for Treatment of Melanoma

  https://www.mdpi.com/1424-8247/17/2/214

  Clinical trials are evaluating pharmacologic agents for the treatment of melanoma, with a particular emphasis on targeted therapy and immunotherapy. The importance of preclinical studies identifying novel therapeutic targets cannot be understated. Current preclinical studies have identified new potential targets for precision melanoma therapy, including CD126, chondroitin sulfate proteoglycan 4 (CSPG4), tandem CD70 and B7-H3, and αvβ3 integrin. Furthermore, novel therapeutic strategies are emerging as promising treatment modalities, including oncolytic virus therapy and the interventional augmentation of immunotherapy efficacy. […] Despite the recent advancements in the pharmacologic treatment of advanced melanoma, evaluating and predicting the pharmacologic efficacy in each patient remain challenging. Although immunotherapy continues to revolutionize melanoma treatment, particularly in patients with previously refractory disease, response to immunotherapy remains highly variable among patients and results in long-term survival in about 50% of melanoma patients; therefore, an important area of melanoma immunotherapy research is focused on identifying predictors of immunotherapy response and strategies to augment the efficacy of immunotherapy in refractory patients. […] This review highlights the current treatment landscape and recent advances in melanoma treatment, including targeted therapy, immunotherapy, combination approaches, and emerging therapies.

• #123 Melanoma biology and treatment: a review of novel regulated cell death-based approaches | Cancer Cell International | Full Text

  https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03220-9

  Despite the improved response rate of combined use of BRAF and MEK inhibitors compared with single use, the combination of BRAF and MEK inhibitors for advanced melanoma in patients carrying the BRAF V600E mutation yielded a 50-70% response rate but an approximately 30% 5-year survival rate. […] The treatment options for some types of melanomas, including acral melanoma, mucosal melanoma and uveal melanoma, remain very limited. […] The ideal implantation of combined BRAF/MEK inhibitors and immune checkpoint blocker therapy, the involvement of oncolytic viral vaccines with immunotherapy, new drug development and nanotechnology-based administration systems for melanoma treatment are ongoing. […] Therefore, to increase the response rate of immune checkpoint blocker therapy, nivolumab (anti-PD1 antibody) plus an anti-lymphocyte-activation gene 3 (LAG3) antibody (relatlimab) received approval in the United States for the treatment of unresectable or metastatic melanoma in adult patients in March 2022.

• #124 Understanding Melanoma: Treatment Options for Stage IV Melanoma

  https://www.aimatmelanoma.org/stages-of-melanoma/stage-iv/

  Surgery may be performed to remove cancerous tumors or lymph nodes that have metastasized to other areas of the body, if they are few in number and/or are causing symptoms. Surgical options are typically limited for patients with metastatic melanoma and have to be considered carefully in the context of the overall course of the disease. […] Drug treatment is recommended for Stage IV melanoma. Only one of the FDA approved agents for metastatic melanoma is delivered locally to specific lesions (T-VEC), but all other treatments are systemic therapies that go through the bloodstream to reach and destroy melanoma cells in the body. Treatments can be divided into immunotherapies, targeted therapies, and chemotherapy. […] Clinical trials are research studies to evaluate new therapies and improve cancer care. These studies are responsible for most of the advances in cancer prevention, diagnosis, and treatment. These studies offer access to promising novel therapies that are not yet available outside of clinical trials because they are still investigational. You may be eligible to participate in a clinical trial. […] If you or someone you love has been diagnosed with Stage IV melanoma or is being evaluated for it, this publication is designed to help you and your oncology team evaluate treatment options and identify the different considerations in deciding your treatment course.

• #125 Melanoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq

  Patients who are younger, female, and who have melanomas on their extremities generally have better prognoses. […] Long-term follow-up is important for detection of recurrence, managing long-term effects, and surveillance of new lesions. […] Surgical excision remains the primary modality for treating localized melanoma. […] Localized melanoma is excised with margins proportional to the microstage of the primary lesion. […] Lymphatic mapping and SLNB should be considered to assess the presence of occult metastasis in the regional lymph nodes of patients with primary tumors measuring at least 0.8 mm thick with clinically negative nodes. […] Adjuvant therapy options for patients at high risk of recurrence after complete resection include checkpoint inhibitors and combination signal transduction inhibitor therapy.

• #126 Treatment | Melanoma skin cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/melanoma/treatment

  Treatment depends on how deep the melanoma is and whether it has spread. This is called the stage of the cancer. Treatment also depends on your general health and where the melanoma is on your body. Surgery is the main treatment for melanoma skin cancer. […] Different treatments are available for advanced melanoma skin cancer and melanoma that can not be removed with surgery. […] Treatment can include surgery and cancer drugs such as targeted cancer drugs, immunotherapy and chemotherapy. […] Surgery is the main treatment for melanoma skin cancer. […] You may have targeted cancer drugs or immunotherapy after surgery. […] Radiotherapy isn’t a common treatment for melanoma skin cancer. […] Treatments include targeted cancer drugs, immunotherapy and chemotherapy. They aim to control the cancer, any symptoms you have and improve your quality of life. […] After your treatment, you have follow up appointments and tests. This is to check you don’t have any side effects and that the cancer hasn’t come back.

• #127 Melanoma Skin Cancer Symptoms, Treatment | Froedtert & MCW

  https://www.froedtert.com/skin-cancer/melanoma

  Melanoma is one type of skin cancer. […] But melanoma is highly curable when discovered and treated in its earliest stages. […] Overall, about 94% of people treated for melanoma are still alive five years after diagnosis (NCI SEER data, 2014-2020). […] Doctors dont usually say melanoma is curable, because there is a chance for any stage of melanoma even melanoma treated at an early stage to come back, known in medical terms as recurrence. […] For this reason, it is vital to get regular check-ups and imaging scans as recommended by your doctor. […] Even for the most advanced stages of melanoma, it is not too late to consider treatment. […] Your cancer team will recommend a treatment plan based on your cancers stage. […] Surgery is the first line of treatment for earlier stage melanoma and is performed by a surgical oncologist.

• #128 Melanoma Skin Cancer Symptoms, Treatment | Froedtert & MCW

  https://www.froedtert.com/skin-cancer/melanoma

  Melanoma is one type of skin cancer. […] But melanoma is highly curable when discovered and treated in its earliest stages. […] Overall, about 94% of people treated for melanoma are still alive five years after diagnosis (NCI SEER data, 2014-2020). […] Doctors dont usually say melanoma is curable, because there is a chance for any stage of melanoma even melanoma treated at an early stage to come back, known in medical terms as recurrence. […] For this reason, it is vital to get regular check-ups and imaging scans as recommended by your doctor. […] Even for the most advanced stages of melanoma, it is not too late to consider treatment. […] Your cancer team will recommend a treatment plan based on your cancers stage. […] Surgery is the first line of treatment for earlier stage melanoma and is performed by a surgical oncologist.

• #129

  https://www.nhs.uk/conditions/melanoma-skin-cancer/treatment/

  Melanoma skin cancer can often be treated. The treatment you have will depend on: […] Surgery is the main treatment for melanoma. Radiotherapy, medicines and chemotherapy are also sometimes used. […] You’ll have regular check-ups during and after any treatments. Depending on the stage of your melanoma, you may have tests and scans. […] Surgery is the main treatment for melanoma, especially if it’s found early. […] Several types of surgery can be used to treat melanoma. […] Radiotherapy is sometimes used to reduce the size of large melanomas and help control and relieve your symptoms. […] Targeted medicines aim to stop the cancer growing. Immunotherapy medicines help your immune system find and kill the cancer cells. […] Chemotherapy uses medicines to kill cancer cells. […] If you’ve been diagnosed with advanced melanoma, it might be very hard to treat. It may not be possible to cure the cancer. […] In this situation, the aim of your treatment will be to limit the cancer and its symptoms, and help you live longer.

• #130 Understanding Melanoma: Treatment Options for Stage IV Melanoma

  https://www.aimatmelanoma.org/stages-of-melanoma/stage-iv/

  Stage IV melanoma has traveled beyond the original tumor site and beyond the regional lymph nodes to more distant areas of the body. The most common sites of metastasis for Stage IV melanoma are distant skin and lymph nodes, then lungs, liver, brain, bone, and/or intestines. The level of serum lactate dehydrogenase (LDH) in the blood may or may not be elevated. The level of LDH is an important sign, as it usually indicates overall tumor burden and possibly how aggressive the tumor is—in other words, it usually indicates the amount of cancer in the body. […] Stage IV melanoma is defined by spread beyond the regional lymph nodes to distant sites. […] For Stage IV specifically, treatments include surgery, systemic therapies, radiation therapy, and clinical trials. The FDA has approved several new drugs that have shown improvements in survival. Many experimental treatments are also under investigation and may be available by enrolling in a clinical trial.

• #131 How We Treat Melanoma | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/melanoma/treatment

  Targeted therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules („molecular targets”) that are involved in the growth, progression, and spread of cancer. […] Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells by either eliminating the cells or stopping them from dividing. […] In specific cases when the tumor is confined only to the skin and surgery is not an option, topical therapies that destroy melanoma cells or boost immunity in an area may be used to remove melanoma cells. […] Treatment options may include the following: […] While many new treatments are effective, melanoma can return in the area where it first started or in other parts of the body, such as the lungs or liver. […] Follow-up care is important because if you have had melanoma, you have an increased risk of developing a new melanoma.

• #132 5 Innovative Melanoma Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/melanoma/melanoma-treatment.html

  In collaboration with skilled radiation oncologists, cancer radiation therapy may be used as a component of your melanoma treatment plan. Radiation therapy may sometimes be combined with chemotherapy. […] These innovative treatments, many of which were developed in part at MD Anderson, are designed to take advantage of a new understanding of the molecular alterations that sometimes occur within melanoma tumor cells. […] These innovative treatments help the body’s natural immune response fight the cancer. Immunotherapy generally is used in advanced melanoma when the cancer has spread to other parts of the body. […] MD Anderson offers the most up-to-date and effective chemotherapy options. […] If you have had a melanoma, you are at higher risk of developing new melanomas than someone who has never had a melanoma. […] Melanoma is treated in our Melanoma and Skin Center. […] MD Anderson patients have access to melanoma clinical trials offering promising new treatments that cannot be found anywhere else.

• #133 Get Melanoma Treatment | Cleveland Clinic

  https://my.clevelandclinic.org/services/melanoma-treatment

  Cleveland Clinic leads and takes part in clinical trials of new medications and treatments for melanoma. […] Our team uses diagnostic testing and surgical biopsy to confirm melanoma and see how advanced the cancer is or determine its stage. […] If you have early-stage melanoma, you have a growth (lesion) only in the top layer of skin. We typically treat these melanomas with surgery. It may be the only treatment you need. […] Sometimes, melanomas spread beyond your skin to lymph nodes or other organs. […] Depending on your melanomas stage and location, your care team may recommend: Surgery: This is the most common treatment for melanoma thats spread to your lymph nodes. […] We may need to remove a large section of skin (wide excision) to make sure all cancerous tissue is gone. […] Youll keep seeing our team regularly after melanoma treatment. […] But even though melanoma can be serious, its also treatable when you catch it early and act quickly. […] Our experienced care team will guide you through every step of your skin cancer diagnosis, treatment, recovery and follow-up.

• #134 Immunotherapy and cell therapy expand treatment possibilities for melanoma patients | Stanford Cancer Institute

  https://med.stanford.edu/cancer/about/news/melanoma.html

  Immunotherapy and cell therapy expand treatment possibilities for melanoma patients […] Melanoma is the deadliest form of skin cancer, despite only accounting for 1% of all skin cancers. […] To learn more about current melanoma treatment and advances in treatment, we talked with SCI member Allison Betof Warner, MD, PhD, leader of Stanfords Melanoma Cutaneous Oncology Clinical Research Group. […] Stage 4 melanoma survival rate has drastically improved with immunotherapy […] In the past, the survival outcomes after a stage 4 melanoma diagnosis used to be measured in months, but now more than half of patients live for five years or more after being diagnosed. This is because the standard of care has shifted to immunotherapy, which is exceptionally effective for melanoma in part due to the high tumor mutation burden caused by UV damage.

• #135 Immunotherapy for Melanoma – Cancer Research Institute

  https://www.cancerresearch.org/cancer-types/melanoma

  Immunotherapy has dramatically shifted the treatment landscape for melanoma, significantly enhancing survival rates and offering new hope to those battling this formidable form of skin cancer. […] The advent of checkpoint inhibitors has been a game-changer, particularly for those facing metastatic melanoma, marking a pivotal shift towards more optimistic outcomes for patients. […] Remarkably, the death rates from melanoma have been on a significant decline between 2013 and 2017, a testament to the progress in treatment methodologies. […] Immunotherapy leverages the body’s immune system to identify and attack cancer cells, marking a significant shift from traditional treatments like surgery and chemotherapy. […] The FDA has approved several immunotherapy treatments for melanoma, targeting various aspects of the immune response:

• #136 Melanoma biology and treatment: a review of novel regulated cell death-based approaches | Cancer Cell International | Full Text

  https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03220-9

  Immunotherapy exploits one’s own personal immune system to kill cancer cells. Since the FDA approval of ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody) to treat metastatic melanoma in 2011, immune checkpoint blocker therapy has represented the primary immunotherapy for melanoma, as it targets CTLA4 and PD-1 on T cells or programmed cell death ligand 1 (PD-L1) on tumor cells, enabling them to escape antitumor responses. […] The combined use of anti-PD1 and anti-CTLA4 antibodies yields a better response than the solitary use of either antibody, and approximately half of patients at an advanced stage of melanoma can benefit long-term from immunotherapy. […] In patients carrying the BRAF V600E mutation, the combination of BRAF and MEK inhibitors such as vemurafenib (a BRAF inhibitor) and cobimetinib (a MEK inhibitor) resulted in a better response than BRAF inhibitors alone and led to a treatment response in a small subset of patients with disease progression receiving BRAF inhibitors alone.

• #137 Immunotherapy for Melanoma – Cancer Research Institute

  https://www.cancerresearch.org/cancer-types/melanoma

  Despite the recent advancements in FDA-approved melanoma therapies, many advanced metastatic melanoma patients still face a significant mortality risk. […] Research into immunotherapy for melanoma continues to evolve, with CRI playing a crucial role in funding innovative studies. […] A recent study published by the National Institutes of Health (NIH) shows that immunotherapy improves survival rates for many melanoma patients. […] The effectiveness of immunotherapy can vary, influenced by factors such as the tumor’s characteristics and the patient’s immune response. […] The frequency of immunotherapy administration can vary widely depending on the specific regimen. […] Commonly used and effective treatments include checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy), sometimes used in combination for enhanced effectiveness.

• #138 Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  https://www.mdpi.com/2072-6694/16/8/1571

  Despite the significant progress made in the past two decades much still needs to be done to advance available therapeutic options for melanoma patients, especially those with rare types of melanoma. As demonstrated in some cases with immune checkpoint inhibitors, targeted agents not specific to the tumor (sub)type can be successful and in fact preferential over targeted therapy to achieve better results in a variety of melanoma types. Therefore, it is of great importance to investigate and develop ‘multifaceted’ therapeutics capable of treating various subtypes of the disease.

• #139 Melanoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/melanoma-pharmacologic-treatment/

  Pharmacotherapy is only recommended for treating the rare case of metastatic uveal melanoma. Treatment recommendations from the NCCN Panel depend on where the disease has spread and to what extent. […] Tebentafusp is currently the only FDA-approved treatment for metastatic uveal melanoma. It is a bispecific protein containing an anti-CD3 effector and a T-cell receptor that activates T cell-mediated immunity against uveal melanoma cells.

• #140 Immunotherapy and cell therapy expand treatment possibilities for melanoma patients | Stanford Cancer Institute

  https://med.stanford.edu/cancer/about/news/melanoma.html

  Future treatments will need to address less immune-responsive tumors […] An important area of research concerns treating less immune-responsive tumors. […] Finding innovative ways to boost the immune system to improve treatment response is another area of important research. […] Further advances will require an interdisciplinary approach […] Betof speaks with excitement about how the Stanford Melanoma Cutaneous Oncology Clinical Research Group unites the expertise of several different departments across Stanford to treat patients, which include groups in cellular therapy, solid tumor malignancies, and bone marrow transplant and hematology services. […] Betof notes that the skys the limit when collaborating with Stanfords cellular therapy experts on advancing cancer treatment.

• #141 Cell Therapy is Now on The Table for Metastatic Melanoma – InventUMPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–button

  https://news.med.miami.edu/cell-therapy-on-the-table-for-metastatic-melanoma/

  Melanoma is very responsive to the immune system. Some immunotherapies work better in this cancer than in other cancer types. Melanoma was also the first cancer for which checkpoint inhibitors were approved. […] “Melanoma was the first tumor where checkpoint inhibitors were found to be effective, and established what we now call the fourth pillar of cancer treatment, adding immunotherapy to surgery, chemotherapy and radiation,” Dr. Lutzky said. “It’s been a really amazing journey that’s happened in melanoma.”

• #142 A Review of Current and Pipeline Drugs for Treatment of Melanoma

  https://www.mdpi.com/1424-8247/17/2/214

  Clinical trials are evaluating pharmacologic agents for the treatment of melanoma, with a particular emphasis on targeted therapy and immunotherapy. The importance of preclinical studies identifying novel therapeutic targets cannot be understated. Current preclinical studies have identified new potential targets for precision melanoma therapy, including CD126, chondroitin sulfate proteoglycan 4 (CSPG4), tandem CD70 and B7-H3, and αvβ3 integrin. Furthermore, novel therapeutic strategies are emerging as promising treatment modalities, including oncolytic virus therapy and the interventional augmentation of immunotherapy efficacy. […] Despite the recent advancements in the pharmacologic treatment of advanced melanoma, evaluating and predicting the pharmacologic efficacy in each patient remain challenging. Although immunotherapy continues to revolutionize melanoma treatment, particularly in patients with previously refractory disease, response to immunotherapy remains highly variable among patients and results in long-term survival in about 50% of melanoma patients; therefore, an important area of melanoma immunotherapy research is focused on identifying predictors of immunotherapy response and strategies to augment the efficacy of immunotherapy in refractory patients. […] This review highlights the current treatment landscape and recent advances in melanoma treatment, including targeted therapy, immunotherapy, combination approaches, and emerging therapies.

• #143 Melanoma biology and treatment: a review of novel regulated cell death-based approaches | Cancer Cell International | Full Text

  https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03220-9

  The development of novel treatments for targeting biomarkers responsible for melanoma progression, as alternatives or as complementary treatments to immunotherapy, is an outcome of recent investigations. […] Therefore, pyroptosis induction may be a strategy to treat melanoma, but to determine how to manipulate pyroptosis to eliminate its tumor suppression effect, more study is needed. […] The application of immunotherapy and targeted therapy has ushered in a new era of melanoma treatment. However, these approaches alone are not sufficient due to treatment resistance and loss of response. Synergistic therapy, combining different treatment modalities, holds great potential and may become the future mainstay of cancer therapy.

• #144 Melanoma biology and treatment: a review of novel regulated cell death-based approaches | Cancer Cell International | Full Text

  https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03220-9

  Immunotherapy exploits one’s own personal immune system to kill cancer cells. Since the FDA approval of ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody) to treat metastatic melanoma in 2011, immune checkpoint blocker therapy has represented the primary immunotherapy for melanoma, as it targets CTLA4 and PD-1 on T cells or programmed cell death ligand 1 (PD-L1) on tumor cells, enabling them to escape antitumor responses. […] The combined use of anti-PD1 and anti-CTLA4 antibodies yields a better response than the solitary use of either antibody, and approximately half of patients at an advanced stage of melanoma can benefit long-term from immunotherapy. […] In patients carrying the BRAF V600E mutation, the combination of BRAF and MEK inhibitors such as vemurafenib (a BRAF inhibitor) and cobimetinib (a MEK inhibitor) resulted in a better response than BRAF inhibitors alone and led to a treatment response in a small subset of patients with disease progression receiving BRAF inhibitors alone.

• #145 Treating Melanoma Skin Cancer | How Is Melanoma Treated? | American Cancer Society

  https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating.html

  If you’ve been diagnosed with melanoma, your treatment team will discuss your treatment options with you. It’s important to weigh the benefits of each treatment option against the possible risks and side effects. […] Based on the stage of the cancer and other factors, your treatment options might include: Surgery for Melanoma Skin Cancer, Immunotherapy for Melanoma Skin Cancer, Targeted Therapy Drugs for Melanoma Skin Cancer, Chemotherapy for Melanoma Skin Cancer, Radiation Therapy for Melanoma Skin Cancer. […] Early-stage melanomas can often be treated with surgery alone, but more advanced cancers often require other treatments. Sometimes more than one type of treatment is used. […] Depending on your situation, you may have different types of doctors on your treatment team. These doctors may include: A dermatologist: a doctor who treats diseases of the skin, A surgical oncologist (or oncologic surgeon): a doctor who uses surgery to treat cancer, A medical oncologist: a doctor who treats cancer with medicines such as chemotherapy, immunotherapy, or targeted therapy, A radiation oncologist: a doctor who treats cancer with radiation therapy.

• #146 Treatment Planning | Stanford Health Care

  https://stanfordhealthcare.org/medical-conditions/cancer/melanoma/patient-care-resources/treatment-planning.html

  Your treatment options will also be determined by the stage of your cancer. We can treat all the stages of melanoma, from the least to the most severe. […] The best treatment for one person might not be the best treatment for another. There are three topics to consider when discussing with your doctor what works best for you. […] Different types of treatment for melanoma have different goals, such as: Destroying or surgically removing cancer cells in the skin to increase the chance of cure; Destroying or surgically removing any cancer cells that may have spread to other parts of the body; Slowing or stopping the growth of cancer; Delaying or preventing cancer from coming back (recurrence); Managing symptoms of incurable cancer or those related to treatment of advanced disease. […] Your care team can help you understand how various treatments can help you achieve your goals. Discuss what you want to be able to do, both during treatment and after it is complete.

• #147 Melanoma – Symptoms, Staging & Treatment | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/melanoma.html

  Melanoma Treatment, therapy […] Our team of internationally recognized experts provides customized treatment for melanoma to ensure you receive the most advanced care with the least impact on your body. […] Each person and each melanoma are different, and at MD Anderson’s Ben Love/El Paso Corporation Melanoma and Skin Center, we use our unique multidisciplinary approach to tailor treatment for melanoma skin cancer specifically to your unique situation. […] Your personal team of experts in melanoma skin cancer may include melanoma surgical oncologists, melanoma medical oncologists, pathologists, dermatologists and dermatologic surgeons, head and neck surgeons, neurosurgeons, plastic surgeons and other surgeons, radiation oncologists, diagnostic radiologists, and other specialists if needed. They work together closely, collaborating and communicating at every step of your treatment. […] Several innovative treatments for melanoma skin cancer are offered at MD Anderson, and many of them were discovered here. Your personalized treatment may include: Lymphatic mapping and sentinel node biopsy, Minimally invasive limb perfusion, Targeted therapies that capitalize on our improved understanding of the molecular alterations within melanoma tumor cells, Adjuvant radiation therapy to help reduce the risk of melanoma coming back after surgery, Treatments for rare forms of melanoma, such as those that begin in the eye (uveal melanoma) or mucosa (for example, vaginal, rectal or sinonasal). […] And we’re constantly researching ways to help the body fight the cancer, including: Immunotherapy, including the latest agents such as ipilimumab, PD-1 and PDL-1 inhibitors, interleukin-2 and adoptive T-cell therapy, Targeted therapies such as BRAF, MEK, multikinase and KIT inhibitors, Combination regimens, Vaccines. […] Since 2004, the National Cancer Institute has awarded MD Anderson a multimillion-dollar Specialized Programs of Research Excellence (SPORE) grant. This means we are able to offer a broad array of clinical trials for melanoma skin cancer. […] New targeted therapies are improving and bringing hope to our patients. […] Melanoma is treated at our Melanoma and Skin Center.

• #148 Immunotherapy and cell therapy expand treatment possibilities for melanoma patients | Stanford Cancer Institute

  https://med.stanford.edu/cancer/about/news/melanoma.html

  Future treatments will need to address less immune-responsive tumors […] An important area of research concerns treating less immune-responsive tumors. […] Finding innovative ways to boost the immune system to improve treatment response is another area of important research. […] Further advances will require an interdisciplinary approach […] Betof speaks with excitement about how the Stanford Melanoma Cutaneous Oncology Clinical Research Group unites the expertise of several different departments across Stanford to treat patients, which include groups in cellular therapy, solid tumor malignancies, and bone marrow transplant and hematology services. […] Betof notes that the skys the limit when collaborating with Stanfords cellular therapy experts on advancing cancer treatment.

Zobacz więcej